On behalf of the Association of Medical Microbiology and Infectious Disease Canada and the Canadian Association for Clinical Microbiology and Infectious Diseases, we would like to welcome you to Charlottetown, Prince Edward Island, for our 10th annual joint meeting on the prevention, diagnosis, and treatment of infectious diseases. Not unlike one of Charlottetown’s more famous conferences, which was hosted here just over 150 years ago, this year’s event promises to deliver excellence in Canadian content and collaboration.

The Central and Scientific Planning Committees have put in long hours to produce an exceptional program for attendees. As anticipated, there will be a variety of poster and oral presentations of research done by our students, resident, fellows, and colleagues, with awards for the best abstracts presented at conference. Attendees will also have the opportunity to attend workshops and plenary sessions focusing on device associated infections and hepatitis C. The state-of-the-art lectures will deal with the ongoing issue of laboratory test utilization and how to deal with the anti-vaccine movement. The education committee has co-developed three integrated symposia for delegates to attend and the special lecture will focus on both basic science and frontline issues in dealing with Ebola.

There are numerous committee meetings during the conference including an open session on the Choosing Wisely Canada campaign. In addition we hope you can participate in the Canadian Foundation for Infectious Diseases Bug Run on Friday evening.

Our annual meeting is made possible through the ongoing support of our conference sponsors. We would like to thank them for their generous support. Please take advantage of the exhibit hall for the opportunity to see what our industry sponsors have available to assist us in our care of patients with infection. This opportunity provides attendees with a unique opportunity to contrast and compare commercial products and services at a single location.

Similar to last year, we will have a welcome reception and dinner on Thursday evening. This is a great opportunity to meet up with old friends and colleagues. More importantly, it provides you with the opportunity to meet new colleagues and potential new collaborators for future endeavors. The closing dinner will be held at the Culinary Institute of Canada.

If you would like to attend please ensure you purchase your tickets as soon as possible.

Our annual meeting is the result of the hard work and commitment of many individuals to deliver a high quality conference, including the volunteer organizers, those who have submitted abstracts and/or are giving presentations, and our delegates. We would like to thank all of you for your efforts and participation as our ongoing success is dependent upon your contributions. The Charlottetown conference builds upon 10 years of collaboration between our two organizations to provide an excellent annual meeting for Canadians at the forefront of fighting infectious diseases. We look forward to meeting with all of you over the next few days and hope that you will have a wonderful time both at the meeting and as you experience Prince Edward Island.

Au nom de l’Association pour la microbiologie médicale et l’infectiologie Canada et de l’Association canadienne de microbiologie clinique et des maladies infectieuses, nous vous souhaitons la bienvenue à Charlottetown, Île-du-Prince-Édouard, pour notre 10e conférence annuelle conjointe sur la prévention, le diagnostic et le traitement des maladies infectieuses. Tout comme une des conférences les plus célèbres tenue à Charlottetown il y a un peu plus de 150 ans, l’excellence sera au cœur de l’événement de cette année, tant pour ce qui est du contenu canadien que de la collaboration.

Les comités de planification générale et scientifique ont consacré d’innombrables heures à la mise au point d’un programme exceptionnel à l’intention des participants. Comme prévu, il y aura une variété de présentations orales et d’affiches sur la recherche menée par nos étudiants, résidents, fellows et collègues. Des prix seront d’ailleurs remis pour les meilleurs résumés présentés dans le cadre de la conférence. Les participants pourront aussi prendre part à des ateliers et à des séances plénières mettant l’accent sur les infections liées aux instruments et sur l’hépatite C. Des exposés à la fine pointe de la technologie traiteront de l’utilisation des tests de laboratoire et du mouvement anti-vaccin, deux questions d’actualité. Le comité de l’éducation a participé à la mise sur pied de trois symposiums intégrés pour les délégués. L’exposé spécial portera sur l’Ebola, tant pour ce qui est des questions liées à la science fondamentale qu’aux situations de première ligne.

De nombreuses réunions de comités ont lieu durant la conférence, dont une séance ouverte sur la campagne Choisir avec soin. De plus, nous espérons que vous pourrez participer à la course amicale, le « Bug Run » de la Fondation canadienne pour les maladies infectieuses, vendredi soir.

Notre conférence annuelle est rendue possible grâce à la contribution continue de nos commanditaires. Nous tenons à les remercier pour leur généreux soutien. Assurez-vous de visiter la Salle des exposants pour voir ce que les commanditaires de notre industrie ont à offrir pour nous aider à disperser des soins aux patients atteints d’infections. Ce lieu offre aux participants la possibilité unique de se retrouver dans un seul endroit pour mettre en contraste et comparer les produits et services offerts sur le marché.

Notre conférence annuelle est rendue possible grâce à la contribution continue de nos commanditaires. Nous tenons à les remercier pour leur généreux soutien. Assurez-vous de visiter la Salle des exposants pour voir ce que les commanditaires de notre industrie ont à offrir pour nous aider à disperser des soins aux patients atteints d’infections. Ce lieu offre aux participants la possibilité unique de se retrouver dans un seul endroit pour mettre en contraste et comparer les produits et services offerts sur le marché.

Our conference is the fruit of hard work and dedication by many individuals to deliver a high quality conference, including the volunteer organizers, those who have submitted abstracts and/or are giving presentations, and our delegates. We would like to thank all of you for your efforts and participation as our ongoing success is dependent upon your contributions. The Charlottetown conference builds upon 10 years of collaboration between our two organizations to provide an excellent annual meeting for Canadians at the forefront of fighting infectious diseases. We look forward to meeting with all of you over the next few days and hope that you will have a wonderful time both at the meeting and as you experience Prince Edward Island.
Objectives

The AMMI Canada - CACMID Annual Conference provides an interactive venue where experts in the fields of microbiology, infectious diseases, infection prevention and control, and public health meet. The conference attracts attendees from across Canada and internationally. As in previous years, the 2015 conference will provide updates on a variety of topics to a diverse audience of clinicians, microbiologists, laboratory technologists, public health professionals, infection prevention and control practitioners, students and residents.

In addition to the pre-meeting workshops, the program will offer plenary sessions, state of the art clinical lectures, a special lecture, integrated symposia, short oral presentations, poster presentations, workshops and interactive clinical vignettes. The 2015 meeting will be a chance for attendees to showcase their research as well as get up to speed with the latest in the areas of microbiology, adult and paediatric infectious diseases and related subjects. Dynamic expert speakers will be invited from across Canada and internationally to ensure another exciting meeting.

In addition to the scientific component, the meeting will provide ample opportunity for attendees to network, exchange ideas, and reconnect with colleagues.

The 2015 meeting will address topics including:

- Difficult to treat organisms
- Device related infections
- Hepatitis C update
- Understanding the anti-vaccine movement
- Appropriate laboratory utilization

AND A WHOLE LOT MORE!

Event Mobi App

Get the Conference on the Go!


Get all the conference information at your fingertips as soon as it becomes available!

It’s easy to use: just access it on your browser on your mobile device or desktop. Save it to your bookmarks or save it to your homepage so you can easily find it again.

Download Event Mobi to get the most out of your conference experience!
It is my pleasure to extend warm greetings to all delegates attending the AMMI Canada – CACMID Annual Conference in historic Charlottetown. Charlottetown has a history dating back to the British in 1763 when the principal settlement was named after Queen Charlotte, wife of King George III.

As a City steeped in history and culture, Charlottetown is the perfect backdrop for hosting conferences and events such as the AMMI Canada – CACMID Annual Conference. We are a City that steps into the spotlight, taking our rightful place on the regional, national and international stage as an award winning premier event destination. Charlottetown was recognized as a Cultural Capital of Canada in 2011 and we are proud of this cultural designation by Canadian Heritage.

As Mayor of Charlottetown, and on behalf of City Council, I would like to personally reinforce our City’s passion for hosting meetings and conferences such as the AMMI Canada – CACMID Annual Conference. We look forward to hosting you in our City and please take the time to enjoy what our City has to offer its visitors and hopefully you will return to your home community with a remembrance of a special time in your life here in Charlottetown.

Welcome to Charlottetown, the “Birthplace of Confederation”.

Sincerely,

Clifford J. Lee
Mayor

Welcome Reception and Stand Up Dinner

Date: Thursday April 16
Time: 1830 – 2030
Location: Exhibit Hall
Room: Gray/Palmer/Pope (Convention Centre)

Join the conference planning committees, speakers, sponsors, exhibitors, and fellow delegates in a relaxed and informal atmosphere, while enjoying culinary delights in a stand up style dinner.

You are invited to attend the 2015 Annual Conference welcome reception and dinner.

Whether you’d like to share your experiences of the conference so far, discuss the day’s biggest debates or simply enjoy a drink and dinner, the welcome reception and dinner is the perfect place to make new acquaintances and catch up with old friends.

 Clifford J. Lee
Mayor

CITY OF CHARLOTTETOWN
P.O. Box 98, Charlottetown, Prince Edward Island
C1A 7K2 www.city.charlottetown.pe.ca
Central Planning Committee (CPC)
Comité de Planification

AMMI Canada
Daniel B. Gregson
President
Central Planning Committee Co-Chair
Caroline Quach
President Elect
A. Mark Joffe
Past President
Isabelle Chiu
Scientific Planning Committee Co-Chair
Mel Krajden
Co-Treasurer
Shariq Haider
Sponsorship Committee Co-Chair

CACMID
Jeff Fuller
President
Central Planning Committee Co-Chair
Jessica Minion
Vice-President
Scientific Planning Committee Co-Chair
Heather Adam
Past President
Matthew W. Gilmour
Co-Treasurer
Paul N. Levet
Meeting Secretary, Abstract Chair
Patricia Simner
Sponsorship Committee Co-Chair

Scientific Planning Committee (SPC)
Comité Scientifique

AMMI Canada
Isabelle Chiu
Co-Chair
Edith Blondel-Hill
Peter Daley
Gerald Evans
Sarah Forgie
Todd Hatchette
Matthew Oughton
David Patrick
Susan Poutanen
Cécile Tremblay
Duncan Webster
Diana Whellams

CACMID
Jessica Minion
Co-Chair
Vanessa Allen
Meghan Dey
Gregory German
Matthew W. Gilmour
Paul Levet
Christine Turenne
Titus Wong

Educational Grants

AMMI Canada
For Associate Members Only

Eligibility
The applicant must be an AMMI Canada associate member in good standing. To be eligible the applicant must register for the AMMI Canada – CACMID Annual Conference 2015 and pay the full student conference registration fee. One-day registrants are not eligible.

Application
An education grant application form will be available at the registration desk during the conference or can be downloaded from the AMMI Canada website – annual conference section (www.ammi.ca). This form can be completed during the conference and handed in at the registration desk, or be completed after the conference and sent to info@ammi.ca or faxed to 613-260-3235.

$250 Cdn
For Associate Members from Nova Scotia and Prince Edward Island*

$500 Cdn
For Associate Members from Québec, Newfoundland and Labrador, New Brunswick

$750 Cdn
For Associate Members from British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, North West Territories, Yukon, Nunavut and The United States

*N.B: Associate members attending from Charlottetown are ineligible for grants.

CACMID
For Technical Staff and Clinical Microbiology Fellows

Eligibility
Applicants must be microbiology laboratory technologists or technicians, or clinical microbiology fellows registered in a Canadian training program (e.g. Canadian College of Microbiologists), and all must be active members of CACMID. Each applicant is eligible for only one grant.

Application
An education grant application form will be available at the registration desk during the conference or can be downloaded from the CACMID website (www.cacmid.ca). This form can be completed during the conference and handed in at the registration desk, or be completed after the conference and mailed to the CACMID Secretary Treasurer (matthew.gilmour@cacmid.ca).

$250 Cdn
For technical staff attending from Prince Edward Island

$500 Cdn
For technical staff attending from Nova Scotia, New Brunswick and Newfoundland and Labrador

$750 Cdn
For technical staff attending from Manitoba, Ontario and Québec

$1,000 Cdn
For technical staff attending from British Columbia, Alberta, Saskatchewan, North West Territories, Yukon, Nunavut, and International

N.B. Clinical microbiology fellows (all must be Canadian residents) may submit itemized expenses with receipts to a maximum of $1,000.
AMMI Canada Council

Daniel B. Gregson (Calgary, AB)
President
Caroline Quach (Montréal, QC)
President-Elect
A. Mark Joffe (Edmonton, AB)
Past President
Mel Krajden (Vancouver, BC)
Treasurer
Deborah Yamamura (Hamilton, ON)
Secretary
Tony Mazzulli (Toronto, ON)
Medical Microbiology Section Chair
Michael Libman (Montréal, QC)
Infectious Disease Section Chair

Members of Council

Steven Drews (Edmonton, AB)
Christian Lavallée (Montréal, QC)
Andrew Morris (Toronto, ON)
Romina Reyes (Vancouver, BC)
Daniel Smyth (Montreal, NB)
Mark Tyndall (Vancouver, BC)

Ex-Officio Members

Diana Whellams (Hamilton, ON)
Associate Committee Chair
Donald Sheppard (Montréal, QC)
Grants and Awards Committee Chair
Isabelle Chiu (Edmonton, AB)
Program Planning Committee Chair

Are You a Member?

To join AMMI Canada please contact:
Deborah Yamamura
Secretary, AMMI Canada
c/o AMMI Canada Secretariat
192 Bank Street, Ottawa, ON K2P 1W8
Toll-free: 1(866)467-1215 (toll free)
Tel.: (613)260-3233 ext. 103
Fax: (613)260-3235
info@ammi.ca
For more information on AMMI Canada visit: www.ammi.ca

To join CACMID please contact:
Matthew W. Gilmour
Secretary Treasurer, CACMID
Scientific Director General, National Public Health Laboratories
National Microbiology Laboratory
1015 Arlington Street, Winnipeg, MB R3E 3R2
Tel.: (204)789-2070
Fax: (204)789-2097
matthew.gilmour@cacmid.ca
For more information on CACMID visit: www.cacmid.ca

CACMID Board

Jeff Fuller (Edmonton, AB)
President
Jessica Minion (Regina, SK)
Vice-President
Heather Adam (Winnipeg, MB)
Past President
Matthew W. Gilmour (Winnipeg, MB)
Secretary

Councillors

Vanessa Allen (Toronto, ON)
Meghan Dey (Ottawa, ON)
Gregory German (Charlottetown, PE)
Paul N. Levett (Saskatoon, SK)
Christine Turenne (Regina, SK)
Titus Wong (Vancouver, BC)

Abstract Review Committee

Heather Adam (Winnipeg, MB)
Vanessa Allen (Toronto, ON)
David Alexander (Regina, SK)
Ana Blanchard (Montréal, QC)
Constantina Boikos (Montréal, QC)
Andrée-Anne Boisvert (Montréal, QC)
Chelsea Caya (Montréal, QC)
Jasmine Chong (Montréal, QC)
Jeanette Comeau (Montréal, QC)
Peter Daley (St. John’s, NF)
Meghan Dey (Ottawa, ON)
Margaret Doll (Montréal, QC)

Élise Fortin (Montréal, QC)
Jeff Fuller (Edmonton, AB)
Matthew W. Gilmour (Winnipeg, MB)
Daniel B. Gregson (Calgary, AB)
A. Mark Joffe (Edmonton, AB)
Jessica Keen (Montreal, QC)
Christian Lavallée (Montréal, QC)
Jason LeBlanc (Halifax, NS)
Tony Mazzulli (Toronto, ON)
Joanna Merckx (Montréal, QC)
Neil Mina (Edmonton, AB)
Jessica Minion (Regina, SK)

Andrew Morris (Toronto, ON)
Shauna O’Donnell (Montréal, QC)
Matthew Oughton (Montreal, QC)
Caroline Quach (Montréal, QC)
Romina Reyes (Burnaby, BC)
Daniel Smyth (Montreal, NB)
Christine Turenne (Regina, SK)
Duncan Webster (Saint John, NB)
Titus Wong (Vancouver, BC)
Deborah Yamamura (Hamilton, ON)
Celebrating 10 years of collaboration

Collaborating Societies

- Alberta Society for Infectious Diseases Société des maladies infectieuses de l’Alberta
- Canadian Association of HIV Research (CAHR)
- Canadian College of Microbiologists (CSM)
- Canadian Society for Medical Laboratory Science Société canadienne de science de laboratoire médical
- Canadian Society of Microbiologists (CSM)
- Canadian Society of Hospital Pharmacists Société canadienne des pharmaciens d’hôpitaux
- Canadian Foundation for Infectious Diseases Fondation canadienne des maladies infectieuses
- Canadian Society of Medical Laboratory Science Société canadienne de science de laboratoire médical
- Canadian Association of Infectious Diseases Société canadienne des maladies infectieuses
- Pan American Society for Clinical Virology Société canadienne de maladies infectieuses

Accreditation

Maximum credits possible: 30.25 hours

A. For specialists certified with the Royal College of Physicians and Surgeons of Canada (RCPSC): This educational event is approved as an Accredited Learning Activity, (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

MAINPORT - Transfer of Hours

The Royal College of Physicians and Surgeons of Canada allows for attendance data of Section 1, Group Learning activities to be transferred directly into participants’ MAINPORT Transfer of Hours. Please indicate your RCPSC ID Number when registering.

B. For specialists certified with the American Medical Association (AMA): Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Please indicate your AMA ID Number when registering.

C. For Fellows and Specialists of the Canadian College of Microbiologists and Diplomats of the American Board of Medical Microbiology: The Canada College of Microbiologists (CCM) accredits the AMMI Canada – CACMID Annual Conference for CE credits. Certificates of continuing education activity are available through the CCM for documentation of attendance and maintenance of certification. A one-hour educational activity is equivalent to one CE credit. Program evaluation forms and record of CE activity can be obtained and returned, once completed, at the conference registration desk or by email to the FCCM co-chair (hadam@dsmanitoba.ca) following the conference.
GENERAL INFORMATION

CONFERENCE EVALUATIONS

The conference uses an online evaluation system.

Conference Attendees: Please click on the links below to access the full conference evaluation and the program evaluations by day:
- Wednesday, April 15, 2015 - CCM Workshop
- Wednesday, April 15, 2015 - Trainees’ Day
- Thursday, April 16, 2015
- Friday, April 17, 2015
- Saturday, April 18, 2015

2015 Conference Evaluation

All evaluations will be made available online on Event Mobi, the AMMI Canada website, and the CACMID website.

The program evaluations by day will not be live until the morning of the specified date. Therefore, you cannot complete Friday’s evaluation on Thursday, as the sessions have not yet taken place.

ABSTRACTS

There will be NO printed version of the abstracts. All abstracts can be found online in the conference sections of the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites. They are also available as a supplement to the Canadian Journal of Infectious Diseases & Medical Microbiology (www.pulsus.com).

DISCLAIMER

The Central Planning and Scientific Planning Committees will make every effort to present the program as published. However, the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the annual conference, for any cause beyond their reasonable control. The above-mentioned are not liable for any loss or inconvenience caused as a result of such alteration. In the event of cancellation of the annual conference, all pre-paid fees will be refunded, however the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents are not liable for any loss or inconvenience caused as a result of such cancellation, and delegates are therefore advised to take out their own travel insurance and extend their policy for personal possessions as the annual conference does not cover individuals against cancellations of bookings or theft or damage of belongings.

HANDOUTS

Handouts will NOT be available at the conference. Following conference, presentations approved by speakers for posting will be uploaded to both the AMMI Canada (www.ammi.ca) and CACMID (www.cacmid.ca) websites.

HOTEL INFORMATION

Delta Prince Edward (Host Hotel)

Situated on the picturesque waterfront, the newly renovated Delta Prince Edward and adjoining PEI Convention Centre are in the heart of downtown Charlottetown. The 4 Diamond, 4.5 Star Hotel is close to shopping, theatre, art galleries, quaint shops, first class restaurants, nightlife and much more.

The Delta Prince Edward offers a resort-like ambience with Maritime hospitality and an exceptional dining experience with an award winning Chef of the Year in our new Water’s Edge Resto Bar & Grill.

The Delta Prince Edward offers many on-site amenities such as an indoor pool, kids pool, full gym and Radiant Reflections Day Spa.

Delta Prince Edward
18 Queen Street Charlottetown,
Prince Edward Island C1A 4A1
Tel.: (902) 566-2222
Toll-free: 1(866) 835-2352
Fax: (902) 566-2282
Check in: 1500
Check out: 1200
Parking: $18.25/day

Radiant Reflections Day Spa
Tel.: (902) 628-1100
Email: radiant@pei.aibn.com

Holman Grand Hotel

Distinctive, urban, and inspiring — the Holman Grand Hotel is one of Charlottetown’s most iconic locales where luxury meets comfort. Situated with stunning views of the Charlottetown Harbour and located in the heart of the Prince Edward Island’s bustling capital Charlottetown.

The Holman Grand
123 Grafton Street Charlottetown,
Prince Edward Island C1A 7M4
Tel.: (902) 367-7777
Toll-free: 1(877) 455-4726
Fax: (902) 367-3250
Check in: 1500
Check out: 1200
Parking: $15.00/day

EXHIBIT HOURS

Room: Gray/Palmer/Pope
(Convention Centre)

THURSDAY APRIL 16
1100 – 1300
1830 – 2030 Welcome Reception and Dinner

FRIDAY APRIL 17
1100 – 1300

The AMMI Canada – CACMID Annual Conference has received tremendous support from our exhibiting companies. We encourage you to visit the exhibit hall to discover the leading edge of business and research in the fields of medical microbiology, infectious diseases, medicine, pharmaceuticals and diagnostics. Morning breaks and lunches will be served in the exhibit hall on Thursday and Friday.

Don’t miss the opportunity to network with colleagues and friends during the Thursday evening welcome reception and dinner!
Charlottetown, PEI

Charlottetown, PEI is increasingly being hailed internationally as a foodie haven, a cultural capital and a favourite coastal hangout. With the city’s laid-back atmosphere and a plethora of delicious dining spots, it’s no wonder this seaside destination shines.

Outdoor patios line the streets and entertainment options overflow from all corners of the city. Charlottetown’s proximity to world-class beaches, golf and theatre make it the ideal place to stay while visiting.

There is something undeniably special about this Island City that you just can’t replicate. The historic brick, the pedestrian friendly streets, the smell of the ocean, and the music floating through the air all contribute to the magic.

For all things Charlottetown and to plan your journey to the Island visit www.DiscoverCharlottetown.com
Merit Awards Presentations

Thursday April 16
1600 - 1630
Room: Sir John A./MacDonald
(Convention Centre)

Masters of Ceremony:
Jessica Minion (Regina, SK)
Caroline Quach (Montréal, QC)

2015 AMMI Canada - Astellas Post Residency Fellowship
Dr. Derek MacFadden is the recipient of this year’s fellowship. Dr. MacFadden is awarded a one-year fellowship for his research proposal entitled: “Developing a Global Map of Regional Antimicrobial Resistance: Resistance Open”.

Presenting the award:
Dean Stuart, Senior Sales Manager, Immunology and Critical Care, Astellas Pharma Canada, Inc.

2015 AMMI Canada Honorary Membership
Dr. Michael Mulvey is presented this award in recognition of his ongoing work in the fields of antimicrobial resistance and hospital-acquired infections with the National Microbiology Lab (NML), where he serves as Chief of Antimicrobial Resistance and Nosocomial Infections.

Presenting the award:
Daniel B. Gregson, President AMMI Canada

2015 AMMI Canada Distinguished Service Award
Dr. B. Lynn Johnston is presented this award in recognition of her contributions to AMMI Canada and the profession of Infectious Disease as a whole. Dr. Johnston served as President of AMMI Canada from 2010-2012, and then Past-President from 2012-2014, during which she served as the Chair of the Communications and Public Relations Committee and the Nominations Committee.

During her time as President, Dr. Johnston heralded the development of a strategic planning process, during which time AMMI Canada identified its Vision and Mission and outlined its six strategic planning goals and initiatives.

Dr. Johnston’s contributions to the field of infectious disease extend internationally, nationally, provincially, and locally, volunteering her time with too many committees to list.

Presenting the award:
Daniel B. Gregson, President AMMI Canada

2015 AMMI Canada Lifetime Achievement Award
Dr. Lorne Tyrrell is presented the award in recognition of his ongoing mentorship contributions, excellent history of clinical care, and storied research experience. Dr. Tyrrell has provided his experience to 29 graduate students and 18 postdoctoral fellows. He is author and co-author of 198 published papers, 18 book chapters, 383 abstracts, and 2 reports.

It is for Dr. Tyrrell’s commitment to clinical care, education, and research that he is presented this award.

Presenting the award:
Daniel B. Gregson, President AMMI Canada

2015 AMMI Canada Outstanding Microbiologist Award
Kathy Bernard is the recipient of the 2015 AMMI Canada Outstanding Microbiologist Award. Kathy has served as head of the National Microbiology Laboratories Special Bacteriology Unit for 24 years. She is Canada’s “Detective-in-Chief” for human bacterial pathogens. Her expertise on unusual, rare or novel bacterial pathogens has gained her international recognition, sought-out in the form of >100 invited lectures, workshops and webinars, and editorial responsibilities of highly-respected journals and of the prominent Manual of Clinical Microbiology. She has served on numerous committees including the CLSI and International Committee for Systematics of Prokaryotes.

Her contributions to bioterrorism response has garnered her the Queen Elizabeth II Golden Jubilee Commemorative Medal.

Kathy has authored approximately 100 journal articles and book chapters most frequently regarding gram-positive bacilli. For over 35 years, her dedication to solving and sorting bacteriological puzzles has been a team effort. She has warm-heartedly mentored a generation’s worth of students, technologists, fellows, and residents across the country. The occasional isolation of Trueperella bernardiae in the laboratory is one way that her impact in the field of clinical microbiology will always be remembered.

Dr. John G. FitzGerald, who also was originally from south-western Ontario, would be impressed with Kathy’s national and international impact in clinical microbiology.

Presenting the award:
Jeff Fuller, President CACMID
Canadian College of Microbiologists (CCM) Distinguished Service Award

The Canadian College of Microbiologists (CCM) Distinguished Service Award is given to members of the Canadian College of Microbiologists in recognition of outstanding professional contributions to the field of microbiology in Canada in the areas of research, teaching and involvement in the Canadian College of Microbiologists. The recipient of the award this year is Dr. Graham Tipples from the Provincial Laboratory for Public Health (ProvLab) at the University of Alberta Hospital.

Presenting the award: Marc Desjardins, President CCM

Canadian Foundation for Infectious Diseases (CFID) Dr. Juan A. Embil Award for Excellence in Infectious Diseases Research

Dr. Derek MacFadden is the recipient of this award. This award celebrates the commitment of a member of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada to inspiring interest and excitement in the field of infectious diseases. The award recognizes clinical specialists in infectious diseases who have performed extraordinary service as role models and mentors to junior clinicians, faculty, fellows, and students involved in the field of infectious diseases.

Presenting the award: Susan Richardson, President CFID

AMMI Canada Medical Student Research Award

The recipient of this award is Christina Thornton (University of Calgary). The goal of this award is to provide support for medical students who are interested in research in infectious diseases and microbiology who are supervised by an AMMI Canada member.

Presenting the award: Susan Richardson, President CFID

Canadian Foundation for Infectious Diseases (CFID) Dr. John M. Embil Mentorship Award in Infectious Diseases

Dr. Sharon Walmsley is the recipient of this award. This award celebrates the commitment of a member of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada to inspiring interest and excitement in the field of infectious diseases. The award recognizes clinical specialists in infectious diseases who have performed extraordinary service as role models and mentors to junior clinicians, faculty, fellows, and students involved in the field of infectious diseases.

Presenting the award: Susan Richardson, President CFID

Canadian Foundation for Infectious Diseases (CFID) Safe Drinking Water Grant

Dr. Anna Majury is the recipient of this award for her proposal entitled “Metagenomic analysis of drinking well water for rural and marginalized populations in regional Ontario—implications for testing, including human, public and environmental health”.

The CFID Safe Drinking Water Pilot Project Grant was established as seed funding for the promotion of studies investigating one of Canada’s most valuable resources, water.

Presenting the award: Susan Richardson, President CFID

AMMI Canada Medical Student Research Award

There are two recipients of this award:
1. Christopher Chiang, McMaster University
2. Melissa Phuong, University of Toronto

The CFID Summer Student Research Awards were established to attract bright young minds with outstanding academic records to the field of infectious diseases, microbiology, and infection control; and to fulfill the CFID mission of supporting research in infectious diseases.

Presenting the award: Susan Richardson, President CFID

Canadian Foundation for Infectious Diseases (CFID) Dr. Lindsay E. Nicolle Editorial Award

This award is given annually in honour of Dr. Lindsay E. Nicolle, the Founding Editor-in-Chief of The Canadian Journal of Infectious Diseases & Medical Microbiology. This award is given to an individual who has made a significant contribution to infectious diseases and medical microbiology as demonstrated by the impact of their original research published in The Canadian Journal of Infectious Diseases & Medical Microbiology.

Presenting the award: Robert Kalina, President PulSus Group
Poster Awards Presentations

Saturday April 18
1600 – 1615
Masters of Ceremony:
Jessica Minion (Regina, SK)
Caroline Quach (Montreal, QC)

Awards will be presented to the six best poster presentations by students/trainees. Each of the following awards consists of $800 and an engraved plaque:

Association of Medical Microbiology and Infectious Disease (AMMI) Canada Poster Award
Presenting the award:
Daniel B. Gregson, President AMMI Canada

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Poster Award
Presenting the award:
Jeff Fuller, President CACMID

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Technologist Poster Award
Presenting the award:
Jeff Fuller, President CACMID

Canadian College of Microbiologists (CCM) Poster Award
Presenting the award:
Marc Desjardins, President CCM

Canadian Journal of Infectious Diseases and Medical Microbiology (CJIDMM) Trainee Review Article Award
Dr. Gauri Shah is the recipient of the 2014 CJIDMM Trainee Review Article Award for her article, “The particulars on parechovirus”, CJIDMM 25.4 (July/August 2014): 186-188.

Canadian Journal of Infectious Diseases and Medical Microbiology (CJIDMM) Abstract Award
This award is given annually to the best abstract by a trainee on a pediatric topic. It is presented in honour of Dr. Susan King. Funds for this award are generously provided by the PICNIC team and the Hospital for Sick Children (Division of Infectious Diseases).
Presenting the award:
Joan Robinson, Chair PICNIC

Canadian Journal of Infectious Diseases and Medical Microbiology (CJIDMM) Dr. Kenneth Rozee Memorial Poster Award

Closing Dinner

Date: Saturday April 18
Time: 1900 – 2200
Location: Culinary Institute of Canada

Come for the food. Savour the experience.
Enjoy world class chefs preparing extraordinary culinary creations using the very best the fields and waters of PEI have to offer. Take in the entertainment as three-time male vocalist of the year, Eddie Quinn, and his band, perform music celebrating the Island’s rich Celtic history, its landscape, and its people.

Registration for the Closing Dinner is easy — just use the same online registration system as used for the Annual Conference and select the extra sessions you wish to attend. For more information visit the Annual Conference sections of either the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites.

The following award consists of $500 and an engraved plaque:

Dr. Susan King Paediatric Abstract Award
This award is given annually to the best abstract by a trainee on a pediatric topic. It is presented in honour of Dr. Susan King. Funds for this award are generously provided by the PICNIC team and the Hospital for Sick Children (Division of Infectious Diseases).
Presenting the award:
Joan Robinson, Chair PICNIC

This award consists of $500 and an engraved plaque:

Dr. Susan King Paediatric Abstract Award
This award is given annually to the best abstract by a trainee on a pediatric topic. It is presented in honour of Dr. Susan King. Funds for this award are generously provided by the PICNIC team and the Hospital for Sick Children (Division of Infectious Diseases).
Presenting the award:
Joan Robinson, Chair PICNIC

Dr. Kenneth Rozee Memorial Poster Award
Presenting the award:
Marc Desjardins, President CCM
The AMMI Canada – CACMID Special Lecture

Thursday April 16
1630 – 1830
Room: Sir John A./MacDonald (Convention Centre)

Moderators:
Jeff Fuller (EDMONTON, AB)
Daniel B. Gregson (CALGARY, AB)

Ebola Vaccines and Therapeutics
Speaker:
Darryl Falzarano (SASKATOON, SK)

Objectives:
At the end of this session, the participant should be able to:
• Outline basic pathogenesis
• Describe therapeutic development and antivirals
• Realize the difficulties in moving vaccines and therapeutics from bench to bedside

Dr. Darryl Falzarano is a Research Scientist at the Vaccine and Infectious Disease Organization – International Vaccine Center (VIDO-InterVac) at the University of Saskatchewan. He received his Ph.D. from the Department of Medical Microbiology at the University of Manitoba in 2010 for determining the functional importance of post-translation modifications of Ebola virus glycoproteins. He then went on to do a post-doc at Rocky Mountain Laboratories, part of the National Institute of Allergy and Infectious Disease, in Hamilton, MT where he investigated antiviral and immunomodulation strategies for Ebola and Middle East respiratory syndrome coronavirus (MERS-CoV). This included the development of a new animal model and the first potential treatment for MERS-CoV. Dr. Falzarano has 10 years of experience working in high containment (CL-3 and CL-4) laboratories with Ebola, Marburg, MERS-CoV and Lassa. While at the NIH he received the Norman P. Salzmann Memorial Award and Lecture in Virology, was the Kuan-Teh Jeang Scholar for Excellence in Virology, was a member of the teams that received the NIH Director’s Award and the NIH Merit Award.

Ebola Virus Disease Outbreak 2014/2015: Lessons Learned in the Front Line Response
Speaker:
Adrienne Chan (TORONTO, ON)

Objectives:
At the end of this session, the participant should be able to:
• Discuss the epidemiology of the 2014/2015 outbreak in West Africa
• Discuss lessons learned from the current field response from the WHO Clinical Team
• Describe the front line response from an IPC and clinical case management perspective

Dr. Adrienne K. Chan is an Infectious Diseases physician and Assistant Professor of Medicine at the University of Toronto. Currently, Dr. Chan serves as Medical Advisor with Dignitas International and is a staff physician at Sunnybrook Health Sciences Centre, Toronto. Dr. Chan’s areas of interest include HIV care and treatment decentralization in low resource settings, integration of TB and HIV services, optimization of Prevention of Mother-To-Child Transmission (PMTCT) initiatives, and innovative task-shifting models in human resources for health. She holds a cross-appointment to the Global Health Division at the Dalla Lana School of Public Health and the Institute for Health Policy, Management and Evaluation at the University of Toronto, where she teaches on Health Systems Management in International Settings.

Over the last nine years, Dr. Chan has worked in southern Africa with clinical experience in Malawi, Lesotho and Zimbabwe. In 2007, Dr. Chan joined Dignitas International, a Canadian non-government organization, as the organization’s HIV Clinic Coordinator in Zomba, Malawi, and later became Medical Coordinator for the Malawi country program. She was seconded to the World Health Organization in 2014/15 as a Clinical Consultant for the Department of Pandemic and Epidemic Diseases, to support the Ebola response in Sierra Leone.

Dr. Chan trained in Internal Medicine and Infectious Diseases at the University of Toronto, where she served as Chief Medical Resident. She earned an MD from the University of Toronto, Faculty of Medicine and a Masters in Public Health (Frank Knox Memorial Fellow) at Harvard School of Public Health.

Panel Discussion
### Association, Committee & Other Group Meetings

#### Wednesday April 15

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800 – 1630</td>
<td>AMMI Canada Council Meeting</td>
<td>Tupper (Convention Centre)</td>
<td>Daniel B. Gregson</td>
</tr>
<tr>
<td>1230 – 1700</td>
<td>Canadian Public Health Laboratory Network Meeting</td>
<td>Brown (Delta)</td>
<td>Matthew W. Gilmour</td>
</tr>
<tr>
<td>1400 – 1600</td>
<td>CCM Board Meeting</td>
<td>Alexander Galt (Convention Centre)</td>
<td>Marc Desjardins</td>
</tr>
<tr>
<td>1800 – 2000</td>
<td>Atlantic HCV Meeting</td>
<td>Tilley (Convention Centre)</td>
<td>Daniel Smyth, Duncan Webster</td>
</tr>
<tr>
<td>1800 – 2030</td>
<td>CACMID Board Meeting</td>
<td>Tupper (Convention Centre)</td>
<td>Jeff Fuller</td>
</tr>
</tbody>
</table>

#### Thursday April 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 0845</td>
<td>AMMI Canada AGM and Sections Meetings</td>
<td>Archibald/Campbell/Cartier/Langevin (Convention Centre)</td>
<td>Daniel B. Gregson</td>
</tr>
<tr>
<td>1200 – 1400</td>
<td>Royal College MM Specialty Committee Meeting</td>
<td>Tilley (Convention Centre)</td>
<td>David Haldane</td>
</tr>
</tbody>
</table>

#### Friday April 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 0830</td>
<td>Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Annual Meeting</td>
<td>JH Gray (Delta)</td>
<td>Joanne Langley</td>
</tr>
<tr>
<td>1200 – 1400</td>
<td>CCM AGM</td>
<td>Tupper (Convention Centre)</td>
<td>Marc Desjardins</td>
</tr>
<tr>
<td>1230 – 1430</td>
<td>Canadian Hospital Epidemiology Committee (CHEC) Annual Meeting</td>
<td>JH Gray (Convention Centre)</td>
<td>Lynora Saxinger</td>
</tr>
<tr>
<td>1400 – 1600</td>
<td>CCM AGM</td>
<td>Tupper (Convention Centre)</td>
<td>Marc Desjardins</td>
</tr>
<tr>
<td>1745 – 2000</td>
<td>AMMI Canada Antimicrobial Stewardship and Resistance Committee Meeting</td>
<td>Tilley (Convention Centre)</td>
<td>Lynora Saxinger</td>
</tr>
<tr>
<td>1800 – 2030</td>
<td>CACMID AGM</td>
<td>Tupper (Convention Centre)</td>
<td>John Conly</td>
</tr>
<tr>
<td>1830 – 2000</td>
<td>Canadian Journal of Infectious Diseases and Medical Microbiology (CJIDMM) Editorial Board Meeting</td>
<td>JH Gray (Convention Centre)</td>
<td>John Conly</td>
</tr>
</tbody>
</table>

#### Saturday April 18

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>1230 – 1430</td>
<td>Choosing Wisely Canada Campaign Meeting</td>
<td>Tupper (Convention Centre)</td>
<td>Lynora Saxinger</td>
</tr>
</tbody>
</table>

---

### Integrated Symposia

- **Thursday April 16**
  - 1230 – 1430 Hosted by Cubist Pharmaceuticals Canada, Inc, affiliate of Merck Canada
  - Challenges and Opportunities in Preventing and Managing Serious Bacterial Infections

- **Friday April 17**
  - 1230 – 1430 Hosted by Pfizer Canada Inc.
  - Perspectives on Adult Pneumococcal Vaccination: An Interactive Discussion

- **Saturday April 18**
  - 1230 – 1430 Hosted by Merck Canada
  - Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients

### Workshops

- **Thursday April 16**
  - 0715 – 0845 Hosted by Gilead Sciences Canada
  - An Update on the NEW (2015) Canadian HCV Treatment Guidelines

- **Friday April 17**
  - 0715 - 0845 Hosted by Sunovion Pharmaceuticals Canada
  - Is it Time to Replace Vancomycin?

- **Saturday April 18**
  - 0715 - 0845 Hosted by Bristol-Myers Squibb
  - Addressing Unmet Medical Needs in Genotype 3 HCV: A Case-based Approach
CCM Workshop
Viral Hemorrhagic Fevers and other emerging viruses - The impact on laboratory testing

Canadian College of Microbiologists

College Canadien des Microbiologistes

Date: Wednesday April 15
Time: 0800 – 1200
Cost: $80 plus 14% HST

Information on the requirements for membership in the Canadian College of Microbiologists is available at www.ccm.ca.

Trainees’ Day

Wednesday April 15
1230 – 1800 (LUNCH PROVIDED)
No Fee Required

Trainees’ Day is an afternoon of interactive sessions for trainees in adult and paediatric infectious disease and clinical and medical microbiology, held at the AMMI Canada – CACMID Annual Conference 2015. Sessions provide a chance to hear from experts in the field about topics outside of the conventional medical curriculum, with a focus on professional development and employment options. It’s also a great opportunity to meet peers and future colleagues from around the country.

Attendance is free of charge for all trainees, but for planning purposes we ask that you please register only if you are able to attend, and to notify the conference secretariat should your plans change for food and beverage planning purposes.

1230 – 1300
Lunch & Registration
How to Teach
Speaker: Sarah Forgie (Edmonton, AB)

1300 – 1345
Contract Negotiations
Speakers: Susan Richardson (Toronto, ON), Alexander Wong (Regina, SK)

1345 – 1445
Break

1445 – 1500
Human Resource Management
Speaker: Cheryl Main (Hamilton, ON)

1500 – 1600
Emerging Viral Infections - What We Need to Worry About
Speaker: Michael Drebot, Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada

1600 – 1700
Mentorship
Speakers: Christopher Lowe (Vancouver, BC), Penny Barnes (Halifax, NS)

1700 – 1800
Trainees’ Day Reception

Trainees’ Day and the CCM Workshop are the perfect complements to the AMMI Canada – CACMID Annual Conference. Both are optional and open to everyone interested - even if they are not attending the conference.

To register for these activities please visit the annual conference sections of either the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites and follow the instructions to register online.

CCM Annual General Meeting
Thursday April 16
1230 - 1400
Due to the important nature of the special resolution to be passed at the 2015 CCM AGM, the Board of Directors would like to encourage ALL CCM voting members to make an effort to ensure their attendance.
### Program

**Wednesday April 15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0730 – 1200</td>
<td><strong>CCM Workshop</strong> (3.5 hours)</td>
</tr>
<tr>
<td></td>
<td>Viral Hemorrhagic Fevers and Other Emerging Viruses - The Impact on Laboratory Testing</td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Langevin/Tilley (Convention Centre)</td>
</tr>
<tr>
<td></td>
<td>EBOLA in West Africa - Anatomy of the Outbreak and Canada's Response</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Jim Strong (WINNIPEG, MB)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Describe the preparations undertaken by the National Microbiology Laboratory (NML) in the past decade to respond to imported cases and outbreaks of Ebola and better understand the pathogenesis, transmission and ecology of the virus</td>
</tr>
<tr>
<td>0800 – 1630</td>
<td><strong>AMMI Canada Council Meeting</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Tupper (Convention Centre)</td>
</tr>
<tr>
<td>1230 – 1700</td>
<td><strong>Trainees’ Day</strong> (4 hours)</td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Archibald/Cambell/Carlier (Convention Centre)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Diana Whellams (HAMILTON, ON)</td>
</tr>
<tr>
<td></td>
<td><strong>Lunch and Registration</strong></td>
</tr>
<tr>
<td></td>
<td><strong>How to Teach</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Sarah Forgie (EDMONTON, AB)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Define medutainment</td>
</tr>
<tr>
<td></td>
<td>• Create a teaching vignette using medutainment principles</td>
</tr>
<tr>
<td></td>
<td>• Design a session in your own field using medutainment principles</td>
</tr>
<tr>
<td>1230 - 1300</td>
<td><strong>Contract Negotiations</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Susan Richardson (TORONTO, ON)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Understand the selection process for new hires in an academic vs. non-academic setting</td>
</tr>
<tr>
<td></td>
<td>• Understand how and by whom the contract negotiation process is carried out, and what components will or should be under discussion</td>
</tr>
<tr>
<td></td>
<td>• Understand common pitfalls and also resources available to the resident involved in the negotiation process</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Alexander Wong (REGINA, SK)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Define key concepts of job satisfaction and happiness</td>
</tr>
<tr>
<td>1400 – 1600</td>
<td><strong>CCM Board Meeting</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Alexander Galt (Convention Centre)</td>
</tr>
<tr>
<td>1700 – 1800</td>
<td><strong>Trainees’ Day Reception</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Cartier (Convention Centre)</td>
</tr>
<tr>
<td>1800 – 2000</td>
<td><strong>Atlantic HCV Meeting</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Tilley (Convention Centre)</td>
</tr>
<tr>
<td>1800 – 2030</td>
<td><strong>CACMID Board Meeting</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Tupper (Convention Centre)</td>
</tr>
<tr>
<td>0730 – 1200</td>
<td><strong>Emerging Viral Infections - What We Need to Worry About</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Micheal Drebot (WINNIPEG, MB)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Provide an overview of selected viral pathogens that have recently emerged as a global concern</td>
</tr>
<tr>
<td></td>
<td>• Describe the challenges and laboratory testing considerations when developing diagnostic algorithms for identifying cases associated with newly emerging viruses</td>
</tr>
<tr>
<td></td>
<td>• Describe novel approaches for identifying unknown pathogens and attributing disease causality</td>
</tr>
<tr>
<td>1800 – 1930</td>
<td><strong>Human Resource Management</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Cheryl Main (HAMILTON, ON)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Identify career opportunities and negotiate for a position</td>
</tr>
<tr>
<td></td>
<td>• Compare and contrast academic vs. community-based positions, and fee-for-services vs. alternatively-remunerated positions</td>
</tr>
<tr>
<td>1930 – 2100</td>
<td><strong>Mentorship</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Christopher Lowe (VANCOUVER, BC)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Identify attributes in a mentor to create a successful relationship</td>
</tr>
<tr>
<td></td>
<td>• Describe expectations of a mentee</td>
</tr>
<tr>
<td></td>
<td>• Discuss strategies of approaching and finding a mentor</td>
</tr>
<tr>
<td>1930 – 2100</td>
<td><strong>How to Teach</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Penny Barnes (HALIFAX, NS)</td>
</tr>
<tr>
<td></td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td></td>
<td>• Define various forms of mentorship</td>
</tr>
<tr>
<td></td>
<td>• Define the characteristics of an ideal mentor</td>
</tr>
<tr>
<td></td>
<td>• Review the benefits of a mentoring relationship</td>
</tr>
</tbody>
</table>
Thursday April 16

0700 – 0845 AMMI Canada AGM and Sections Meetings
Room: Archibald/Campbell/Cartier/Langevin (Convention Centre)

0715 – 0845 Workshop (1 hour)
co-developed by AMMI Canada and Gilead Sciences Canada
An Update on the NEW (2015) Canadian HCV Treatment Guidelines
Room: Tupper (Convention Centre)
Moderator: Titus Wong (Vancouver, BC)
Speaker: Stephen Shafran (Edmonton, AB)

Objectives:
By the end of this program, participants will have a better understanding of:
• The 2015 Canadian Hepatitis C guidelines
• The clinical use of IFN-Free treatment of HCV infection in a variety of patient types

0845 – 0900 Break
Room: Foyer (Convention Centre)

0900 – 1100 Plenary (2 hours)
Difficult to Treat Organisms
Room: Sir John A./Macdonald (Convention Centre)
Moderator: Susan Poutanen (Toronto, ON)
Christine Turenne (Regina, SK)

The CDC Big Three: Challenges from the Laboratory Perspective
Speaker: Todd Hatchette (Halifax, NS)

Objectives:
At the end of the session, the participant should be able to:
• Describe the capabilities and challenges of novel tools used for the detection of carbapenemase-producing organisms
• Contrast Clostridium difficile testing algorithms: Are labs using the best strategy?
• Describe the impact of current laboratory practices as it relates to Neisseria gonorrhoeae

0940 – 1020 Keystone Isn’t the Only Challenging Pipeline: Antimicrobials for Difficult to Treat Organisms
Speaker: Gerald Evans (Kingston, ON)

Objectives:
At the end of the session, the participant should be able to:
• Explain the challenges in developing new antimicrobials for difficult to treat organisms
• Outline the chief therapeutic strategies for antimicrobial therapy of difficult to treat organisms
• Envisage the steps needed and barriers to implementing new antimicrobials for difficult to treat organisms

1020 – 1100 Good Kindergarten Lessons Gone Bad: Stop Sharing Now!
Speaker: Mark Joffe (Edmonton, AB)

Objectives:
At the end of the session, the participant should be able to:
• Apply the advances in infection control pertinent to management of Clostridium difficile and Carbapenemase-Producing Organisms
• Describe existing and novel approaches to public health management of gonococcal infection

1100 – 1130 Break (In Exhibit Hall)
Room: Gray/Palmer/Pope (Convention Centre)

1100 – 1230 Exhibit Hall Open
Room: Gray/Palmer/Pope (Convention Centre)

1100 – 1300 Student Poster Judging
(presenters at posters)
Room: Coles (Convention Centre)

1200 – 1400 Royal College MM Specialty Committee Meeting
Room: Tilley (Convention Centre)

1200 – 1400 Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Annual Meeting
Room: JH Gray (Convention Centre)

1230 – 1300 Exhibit Hall Lunch
Room: Gray/Palmer/Pope (Convention Centre)

1230 – 1400 CCM AGM
Room: Tupper (Convention Centre)

1230 – 1300 Integrated Symposium
(1.5 hours)
co-developed by AMMI Canada and Cubist Pharmaceuticals, Inc, affiliate of Merck Canada
Challenges and Opportunities in Preventing and Managing Serious Bacterial Infections
Room: Archibald/Campbell/Cartier/Langevin (Convention Centre)
Moderator: Matthew Oughton (Montreal, QC)
Speakers: Andrew E. Simor (Toronto, ON)
Susan Poutanen (Toronto, ON)
Christine Lee (Hamilton, ON)

Objectives:
By the end of this program, participants will have a better understanding of:
• Evidence-based guideline recommendations into clinical practice when managing hospitalized patients with serious bacterial infections
• How to optimize the use of available strategies to prevent and manage multi-drug resistant bacterial infections by considering patient and pathogen factors

1300 – 1315 Break
Room: Foyer (Convention Centre)

1400 – 1530 Oral Presentations (1 hour)
Session A
Room: Henry (Delta)
Moderator: Susan Poutanen (Toronto, ON)

A01 1445 – 1500 Susceptibility Rates and Species Identification of Campylobacter Strains Isolated from Human Enteric Infections in a New Brunswick Regional Hospital.
R. Garcea1, R. Rafaat Gad2, M. Mallet3
1Centre hospitalier universitaire Dr G. L. Dumont, Moncton, NB, 2New Brunswick Public Health, Fredericton, NB, 3Pêches et Océans Canada, Moncton, NB

A02 1500 – 1515 Identification of Shiga-Toxin Producing Escherichia coli (STEC) from Human Stool Specimens Using a Two-Step Algorithm: Chromogenic Media (CM) and Enzyme Immunoassay (EIA)
C. Barth1, N. Neudorf2, D. Daku2, A. Obarianyk3, R. Mcdonald2, P.N. Levet2, G.B. Horman2, N. Mina2, J. Minion1, K. Maleczyk3
1Regina General Hospital Medical Laboratory, Regina, SK, 2Saskatchewan Disease Control Laboratory, Regina, SK

A03 1515 – 1530 Detection of Enteric Pathogens in Patients experiencing Diarrhea by Multi-analyte Platforms
L. Chiu1, S. Latonas2
1Provincial Laboratory for Public Health, Edmonton, AB, 2University of Alberta, Edmonton, AB
Performance and Efficiency of Two Algorithms for *Clostridium difficile* Associated Diarrhea (CDAD) Diagnosis for a Provincial Microbiology Network

P. DALEY1,2, K. WELLS3, J. COLE1, S. TILLER1, R. NEEDLE1, M. HUGHES1, C. PENNEY1
1Memorial University, St. John’s, NL
2Eastern Health Region, St. John’s, NL

Characterization of Canadian Isolates of a Recently-Described Genus and Species Novum, *Eisenbergiella tayi*, of the Family Lachnospiraceae

K. BERNARDI1,2, D. WIEBE1, T. BURDZ1, L. HOANG1, P. LAGACE-WIENS1,2, M. DESJARDINS1
1National Microbiology Laboratory, Winnipeg, MB, 2Department of Medical Microbiology University of Manitoba, Winnipeg, MB, 3BCDC Public Health Microbiology and Reference Laboratory, Vancouver, BC, 4University of Ottawa, Ottawa, ON

Understanding *Pseudomonas aeruginosa* Treatment Resistance in Chronic Lung Infection Using Deep Population Sequencing

B. COBURN1, J. DIAZ CABALLERO1, S. CLARK1,2, P. WANG1, D. DONALDSON1, Y. ZHANG1,2, Y. YAU1, V. WATERS1,4, D.E. TULLIS1,2, S. HVANG1,2, D. GUTTMAN1
1University of Toronto, Toronto, ON, 2University Health Network, Toronto, ON, 3University General Research Institute, Toronto, ON, 4Hospital for Sick Children, Toronto, ON, 5St. Michael's Hospital, Toronto, ON

Antibiotic Therapy Identification Reduces Time to Appropriate Approach for Identification and Orientation and Conventional Culture

Evaluation of MALDI-TOF for Identification and Subspeciation and Correlation with Molecular and Phenotypic Detection of Clarithromycin Resistance in Ontario

F. B. JAMIESON1,2, J. H. MA1, D. LIU1, D. J. FARRELL1
1Public Health Ontario Laboratories, Toronto, ON, 2University of Toronto, Toronto, ON, 3Western University, London, ON

Serotype Distribution and Antimicrobial Susceptibility of Invasive and Noninvasive *Streptococcus pneumoniae* in Canada

A.R. GOLDEN1, H.J. ADAM1,2, M. BAXTER1, K.A. NICHOL2, I. MARTIN3, W. DEMCZUK3, M. GILMOUR1,2, J.A. KARLOWSKY1,2, D.J. HOBAN1,2, G.G. ZHANEL1
1University of Manitoba, Winnipeg, MB, 2Diagnostic Services Manitoba, Winnipeg, MB, 3Toronto Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

1500 – 1515 Break

Room: Foyer (Convention Centre)

Airway Infections: A New Frontier

AMMI Canada – CACMID Special Lecture (2 hours)

Room: Sir John A./MacDonald (Convention Centre)

Moderators: Darryl Falzarano (Saskatoon, SK)

Speaker: Adrienne Chan (Toronto, ON)

Objectives: At the end of this session, the participant should be able to:

- Outline basic pathogenesis
- Describe therapeutic development and antivirals
- Realize the difficulties in moving vaccines and therapeutics from bench to bedside

Ebola Virus Disease Outbreak 2014/2015: Lessons Learned in the Front Line Response

Ebola Vaccines and Therapeutics

Panel Discussion Welcome Reception and Dinner in Exhibit Hall

Room: Gray/Palmer/Pope (Convention Centre)
### Friday April 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 0700 – 0830 | **CFID Board Meeting**  
Room: Alexander Galt  
(Convention Centre) |
| 0715 – 0845 | **Workshop** (1 hour)  
co-developed by AMMI  
Canada and Sunovion Pharmaceuticals Canada  
**Is it Time to Replace Vancomycin?**  
Room: Tupper  
(Convention Centre)  
Speakers:  
Andrew E. Simor *(Toronto, ON)*  
Daniel J.G. Thirion *(Montréal, QC)* |
| 0730 – 0845 | **AMMI Canada Education and Guidelines Committee Meetings**  
Room: JH Gray  
(Convention Centre) |
| 0730 – 0845 | **CACMID AGM**  
Room: Archibald/Campbell/Carter/Langevin  
(Convention Centre) |
| 0845 – 0900 | **Break**  
Room: Foyer (Convention Centre) |
| 0900 – 1130 | **Plenary** (2 hours)  
**Device Related Infections**  
Room: Sir John A./MacDonald  
Moderators:  
Peter Daley *(St. John’s, NL)*  
Matthew W. Gilmour *(Winnipeg, MB)*  
**SHAKE’N BAKE - What’s New in the Diagnosis of Device-Associated Infection?**  
Speaker:  
Robin Patel *(Rochester, MN)*  
**Objectives:**  
- Review the evidence that supports vancomycin use in the treatment of complicated MRSA infections  
- Review the evidence that supports newer agents in the treatment of complicated MRSA infections  
- Discuss the clinical syndromes of MRSA bacteremia and MRSA pneumonia in the context of vancomycin and newer agents  
| 1100 – 1300 | **Break (In Exhibit Hall)**  
Room: Gray/Palmer/Pope  
(Convention Centre) |
| 1100 – 1300 | **Exhibit Hall Open**  
Room: Gray/Palmer/Pope  
(Convention Centre) |
| 1200 – 1400 | **Integrated Symposium** (1.5 hours)  
co-developed by AMMI Canada and Pfizer Canada  
**Perspectives on Adult Pneumococcal Vaccination: An Interactive Discussion**  
Room: Archibald/Campbell/Carter/Langevin  
(Convention Centre)  
Moderator:  
Thomas Marrie *(Halifax, NS)*  
**Speakers:**  
Allison McCabe *(Toronto, ON)*  
Brian Ward *(Montreal, QC)* |
| 1300 – 1400 | **Exhibitor Debrief**  
Room: McDougall (Delta)  
**Break**  
Room: Foyer (Convention Centre) |
| 1430 – 1445 | **State of the Art Clinical Lecture** (1 hour)  
**Laboratory Test Utilization in Microbiology: Where do we begin?**  
Room: Sir John A./MacDonald  
Moderator:  
Susan Poutanen *(Toronto, ON)*  
**Speaker:**  
Christopher Naugler *(Calgary, AB)*  
**Objectives:**  
- Define the principles and need for antimicrobial prophylaxis for implantable devices  
- Outline the preventive strategies for device-associated infections  
- Describe the research gaps in the prevention of device-associated infections  
| 1445 – 1545 | **Panel Discussion** |
| 1545 – 1600 | **Break**  
Room: Foyer (Convention Centre) |
Celebrating 10 years of collaboration Célébrons 10 années de collaboration

**E01 1600 – 1615**
Nursing Advanced Directive to Remove Urinary Catheters Among General Internal Medicine Patients: a Controlled Before-After Study

C. CORPUS¹, B. CATT¹, P. CHO¹, F. WONG¹, S. CALLERY¹, B. WONG¹,², A. SIMOR¹,², ⁴, M. VEARNICOME¹,², ⁴, J. LEIS¹,², ³

¹Sunnybrook Health Sciences Centre, Toronto, ON, ²University of Toronto, Toronto, ON, ³Centre for Quality Improvement and Patient Safety and Department of Medicine, University of Toronto, Toronto, ON, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON

**E02 1615 – 1630**
Impact of Urinary Tract Infection Prophylactic Empiric Treatment Guidelines on Prescribing of Nitrofurantoin in Primary Care and Long Term Care Settings in the Province of Prince Edward Island

J. BOSWELL¹, S. CHUU¹, W. COOKE², I. FERRISH³, G. GERMAN¹

¹Health PEI, Charlottetown, PE, ²Queen Elizabeth Hospital, Charlottetown, PE, ³Prince County Hospital, Summerside, PE

**E03 1630 – 1645**
Early Onset Invasive Candidiasis in Extremely Low Birth Weight Infants: Risks and Outcomes in a Multicentre Canadian Prospective Study


¹Western University, London, ON, ²The Hospital for Sick Children, Toronto, ON, ³Mount Sinai Hospital, Toronto, ON, ⁴Stollery Children’s Hospital, Edmonton, AB, ⁵Foothills Hospital, Calgary, AB, ⁶Sunnybrook Health Sciences Centre, Toronto, ON, ⁷Dalhousie University, Halifax, NS, ⁸Children’s Hospital of Eastern Ontario, Ottawa, ON, ⁹British Columbia’s Women’s Hospital, Vancouver, BC, ¹⁰Royal University Hospital, Saskatoon, SK, ¹¹CHU Sainte-Justine, Montréal, QC, ¹²McMaster University, Hamilton, ON, ¹³Jewish General Hospital, Montréal, QC

**E04 1645 – 1700**
Successful Treatment of Candida Albicans Meningitis with Intrathecal Amphotericin and Intravenous Fluconazole: A Case Report and Review of Literature

B. GHADAKI¹, N. IRFAN², M. LOEB³

¹McMaster University, Hamilton, ON, ²Hamilton Health Sciences, Hamilton, ON, ³Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON

**E05 1700 – 1715**
Linezolid-Resistant MRSA Strains Sequentially Isolated from an Elderly Patient with Pneumonia During Prolonged Therapy with Linezolid

X-K. HAO

Fourth Military Medical University, Xi’an, China

**E06 1715 – 1730**
Comparison of Outcomes between VRE and VSE Bacteremia in the Era of Effective VRE Therapy: A Systematic Review and Meta-Analysis

C. PREMATUNGE⁴, C. MCDOUGALL⁵, J. JOHNSTONE¹,²,³, K. ADOMAKO¹, F. LAM¹, J. ROBERTSON¹, G. GARBER¹,²,³,⁴,⁵

¹Public Health Ontario, Infection Prevention and Control, Toronto, ON, ²St. Joseph’s Health Centre, Toronto, ON, ³University of Toronto, Department of Medicine, Toronto, ON, ⁴University of Ottawa, Department of Medicine, Ottawa, ON, ⁵Ottawa Hospital Research Institute, Ottawa, ON

**F01 1600 – 1615**
Implementation of Siemens Centaur Syphilis Enzyme Immunoassay: BC Experience

A. MAK¹, Y. SIMPSON¹, N. CHAHIL¹, K. CHU¹, Q. WONG¹, M. MORSHED¹,²

¹Public Health and Reference Laboratory, Vancouver, BC, ²UBC Department of Pathology and Laboratory Medicine, Vancouver, BC

**F02 1615 – 1630**
Genetic Diversity and Molecular Evolution of Respiratory Syncytial Virus A ON1 Genotype, 2010-2013: a Comparative Analysis

A. GRANADOS¹,², V.R. DUVVURI¹,³, P. ROSENFELD¹,², A. ESHAGHI¹, J.B. GUBBAY¹,²

¹Public Health Ontario, Toronto, ON, ²University of Toronto, Toronto, ON, ³University of Waterloo, Waterloo, ON

**F03 1630 – 1645**
Shedding of Live-Attenuated Influenza Vaccine (LAV) Viruses in Canadian Children and Adolescents with and without Cystic Fibrosis

C. BOIKO¹, H. CHAREST², J. PAPENBURG³, D. SCHEIFELÉ⁴, L.C. LANDS⁶, G. DESERRES⁴, ⁸, ⁹, ¹⁰, C. QUACH¹,²,³,⁸, ⁹, ¹⁰

¹Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, ²Laboratoire de santé publique du Québec/Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC, ³Department of Pediatrics, Division of Infectious Diseases, The Montréal Children’s Hospital, McGill University, Montréal, QC, ⁴Division of Infectious and Immunological Diseases, Department of Pediatrics, University of British Columbia, ⁵Vaccine Evaluation Centre, Child and Family Research Institute, Vancouver, BC, ⁶Department of Pediatrics, Division of Respiratory Medicine, The Montréal Children’s Hospital, McGill University, Montréal, ⁷Department of Social and Preventive Medicine, Laval University, ⁸Institut national de santé publique du Québec, Québec, ⁹Department of Pediatrics, Division of Infectious Diseases, Centre Mère-Enfant Soleil du CHU de Québec, Québec, ¹⁰McGill University Health Centre, Vaccine Study Centre, Research Institute of the MUHC, Montréal, QC

**F04 1645 – 1700**
The Application of Serological and Molecular Diagnostic Procedures to Identify Travel-Related Chikungunya Cases in Canada 2014

K. DIMITROVA, K. HOLLOWAY, K. MAKOWSKI, M. ANDONOVA, R. LINDSAY, M. DREBOT

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB
Detection of Enterovirus D68 in Canadian Laboratories


1Division of Microbiology, Department of Pathology and Laboratory Medicine, Capital District Health Authority (CDHA), and Department of Pathology, Halifax, NS, 2Dalhousie University, Halifax, NS, 3Provincial Laboratory for Public Health (ProvLab), and Department Laboratory Medicine and Pathology, Edmonton, AB, 4University of Alberta, Edmonton, AB, 5Enterovirus and Enteric Virus Laboratory, National Microbiology Laboratory (NML), Winnipeg, MB, 6Laboratoire de Santé Publique National du Québec (LSPQ)/Institut National de Santé Publique du Québec (INSPQ), Québec, QC, 7Cadmham Provincial Laboratory, Winnipeg, MB, 8Centre Hospitalier Universitaire Dr. George L. Dumont, Moncton, NB, 9Public Health Ontario, Toronto, ON, 10University of Toronto, Toronto, ON, 11EORLA Regional Virology Laboratory, Children’s Hospital of Eastern Ontario (CHEO), Ottawa, ON, 12University of Ottawa, Ottawa, ON, 13Public Health Microbiology and Reference Laboratory, British Columbia Centre for Disease Control (BCCDC), Vancouver, BC, 14Saskatchewan Disease Control Laboratory (SDCL), Ministry of Health, Regina, SK, 15Department of Microbiology, Mount Sinai Hospital and University Health Network, Toronto, ON, 16Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, 17Sunnybrook Health Sciences Centre, Toronto, ON, 18Public Health Laboratory and Microbiology, St. John’s, NL, 19The Hospital for Sick Children, Toronto, ON, 20St-Joseph’s Healthcare, Hamilton, ON, 21University of Calgary, Calgary, AB, 22Medical Microbiology and Immunology, University of Alberta, Edmonton, AB

Evaluation and Comparison of the Luminex® xTAG RVP FAST2, Seegene® Anyplex II RV16 and Seeplex RV15 Viral Respiratory Panel Assays

S. RADKO, J. I. STUART, G. ZAHARIADIS

Western University, London, ON

Comparative Evaluation of Two Phenotypic Tests for Detection of Penicillin Binding Protein 2a (PBP2a) in Diverse Retroviral Clinical Staphylococcus aureus (SA) Isolates

B.M. WILLEY1, P. RAHMAN1, O. LEUNG2, S. DUNNA3, D.N. GROHN4, X. TRIMI5, P. LO1, T. MAZZULLI1,2, S.M. POUTANEN1,2

1Mount Sinai Hospital/University Health Network, Toronto, ON, 2University of Toronto, Toronto, ON, 3University of Western Ontario, London, ON, 4Michener Institute, Toronto, ON

Comparison of Two Broth Enrichment and Two Agars for the Detection of Group B Streptococcus (GBS) from Vaginal-Rectal Screening Specimens

P. LAGACE-WIENS1,2, B. HOSSEINI3, G. POLIQUIN4, S. EDAGIZ5, J.A. KARLOWSKY1,2

1Diagnostic Services Manitoba, Winnipeg, MB, 2University of Manitoba, Winnipeg, MB

Detection of Group A streptococcus (GAS) by Loop-Mediated Isothermal Amplification (LAMP) Directly from Specimens: a Rapid, Simple and Cost-effective Alternative to Culture

P. JAYARATNE1,2, C. RUTHERFORD1,3

1St. Joseph’s Healthcare, Hamilton, ON, 2McMaster University, Hamilton, ON, 3Hamilton Health Sciences, Hamilton, ON

Comprehensive Evaluation of Cepheid’s Xpert Nasal Complete G3 PCR (XNC) on their GeneXpert for Distinguishing Methicillin-Resistant (MR) from Methicillin-Susceptible (MS) Staphylococcus aureus (SA) and Coagulase-Negative Staphylococci (CNS) from isolates

B.M. WILLEY1, O. LEUNG2, P. RAHMAN1, X. TRIMI3, D.N. GROHN4, S. DUNNA3, P. LO1, T. MAZZULLI1,2, S.M. POUTANEN1,2

1Mount Sinai Hospital/University Health Network, Toronto, ON, 2University of Toronto, Toronto, ON, 3University of Western Ontario, London, ON, 4Michener Institute, Toronto, ON

Direct Reporting Cefazolin from Vitek 2 AST N208 for E. coli, K. pneumoniae and P. mirabilis Isolated from Urine Cultures Using 2014 CLSI Interpretation

J. XIONG1, B. LANGFORD2, H. KONG1, D. HANCOCK3, S. KRAJEN1,3, M. DOWNING1, W. CHAPMAN1,3

1Department of Laboratory Medicine, St. Joseph’s Health Center, Toronto, ON, 2Antimicrobial Stewardship, St. Joseph’s Health Center, Toronto, ON, 3University of Toronto, Toronto, ON

Rapid Diagnostic Testing and Lactobacillus reuteri Therapy for Children with Severe Acute Gastroenteritis in Botswana: A Pilot, Factorial, Randomized, Controlled, Clinical Trial

J.M. PERNICA1, A.P. STEENHOFF2,3, M. MOKOMANE4, K. LECHILLE5, J.B. MOORAD2, M. SMIEJA1, L. MAZHANI5, M. LOEB1, K. STORDAL6, D.M. GOLDFARB1,2

1McMaster University, Hamilton, ON, 2Botswana-University Partnership, Gaborone, Botswana, 3Children’s Hospital of Philadelphia, Philadelphia, PA, USA, 4National Health Laboratory, Gaborone, Botswana, 5University of Botswana, Gaborone, Botswana, 6Norwegian Institute of Public Health, Oslo, Norway

Prevalence and Epidemiology of Methicillin-resistant Staphylococcus aureus Colonization in an Aboriginal Community

P. DALEY6, J. BAJGAI4, C. PENNEY1, H. WHITNEY1, G. GOLDING2, D. ALLISON3

1Memorial University, St. John’s, NL, 2National Microbiology Laboratory, Winnipeg, MB

Evaluation of Three Chromogenic Media for Screening Surveillance Specimens for Third Generation Cephalosporin Resistant Enterobacteriaceae

C. RUTHERFORD1, M. PARTOVI1, L. MONKMAN1, D. YAMAMURA1,2

1Hamilton Regional Laboratory Medicine Program, Hamilton, ON, 2McMaster University Department of Pathology and Molecular Medicine, Hamilton, ON

Comparison of the New MRSASelect II, Brilliance MRSA 2 Media with Current Versions of MRSASelect and Denim Blue for the Detection of MRSA

P. KORNHER, H. FAIZULLAH, E. PICKLES, M. SOHRABI

Gamma-Dynacare Medical Laboratories, Ottawa, ON
### H05 1700 – 1715

**A Direct Comparison of Toxigenic Clostridium difficile by Dual Rapid Test Cassette Versus Traditional Enzyme Immune Assay / PCR Algorithmic Methods**

R. MOORE\(^1\), G. GERMAN\(^1,2\)

\(^1\)Prince County Hospital, Summerside, PE, \(^2\)Health PEI, Division of Microbiology, Charlottetown, PE

### H06 1715 – 1730

**Superiority of Real-Time PCR Over Other Antigen Testing for Syphilis Detection**

S. MAN\(^1\), M-K. LEE\(^1\), K. FERNANDO\(^1\), Q. WONG\(^1\), M. MORSHED\(^1,2\)

\(^1\)B.C. Public Health Microbiology and Reference Laboratory, Vancouver, BC, \(^2\)University of British Columbia, Vancouver, BC

### 1745 – 2000

**AMMI Canada Antimicrobial Stewardship and Resistance Committee Meeting**

Room: JH Gray (Convention Centre)

### 1830 – 2000

**CJIDMM Editorial Board Meeting**

Room: Tilleys (Convention Centre)

### 1830 – 2000

**CFID Bug Run**

### 0715 – 0845

<table>
<thead>
<tr>
<th>Workshop (1 hour) co-developed by AMMI Canada and Bristol-Myers Squibb</th>
<th>Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addressing Unmet Medical Needs in Genotype 3 HCV: A Case-based Approach</td>
<td>Room: Foyer (Convention Centre)</td>
</tr>
<tr>
<td><strong>Moderator:</strong> Duncan Webster (Sant John, NB)</td>
<td><strong>School:</strong> Matthew W. Gilmour (Winnipeg, MB)</td>
</tr>
<tr>
<td><strong>Speaker:</strong> Karen Doucette (Edmonton, AB)</td>
<td><strong>Speaker:</strong> Lisa Barrett (Halifax, NS)</td>
</tr>
<tr>
<td>Following their participation in this program, participants will be able to:</td>
<td><strong>Objectives:</strong> At the end of the session, the participant should be able to:</td>
</tr>
<tr>
<td>• Identify the treatment options available to various HCV patient populations</td>
<td>• Relate to the health economic impact of untreated HCV</td>
</tr>
<tr>
<td>• Cite the efficacy, safety and tolerability data of different therapeutic options</td>
<td>• Identify the potential economic impact of increased treatment using novel HCV regimens</td>
</tr>
<tr>
<td>• Recognize the expanding treatment armamentarium of HCV</td>
<td>• Demonstrate novel programming being designed to evaluate clinical, epidemiologic, and economic impact in Atlantic Canada</td>
</tr>
</tbody>
</table>

### 0900 – 1100

**HCV Elimination: Data, Dogma, and Dollars**

**Room:** Sir John A./MacDonald (Convention Centre)

**Moderators:**

Todd Hatchette (Halifax, NS)

Titus Wong (Vancouver, BC)

**Data: Using Surveillance and Molecular Epidemiology to Support HCV Elimination**

**Speaker:** Mel Krajden (Vancouver, BC)

**Objectives:**

At the end of the session, the participant should be able to:

- Emphasize the impact that epidemiology has on policy-making, and that it is not just ‘descriptive numbers’
- Explain how testing strategy will be an integral component to an overall strategy in the elimination of HCV in Canada

### 0930 – 1000

**Dogma: HCV Elimination in the Era of Direct Acting Interferon-Free Agents**

**Speaker:** Lisa Barrett (Halifax, NS)

**Objectives:**

At the end of the session, the participant should be able to:

- Contrast current oral HCV treatment options, including duration and cure rates
- Describe an infectious disease plan for the elimination of HCV
- Predict which key populations should be treated to facilitate elimination

### 1000 – 1030

**Panel Discussion**

### 102 1125 – 1140

**Generation of a Campylobacter jejuni Surveillance Database in Alberta Utilizing the Subtyping Method Comparative Genomic Fingerprinting**

L. CHUI\(^1,2\), A. MA\(^1\)

\(^1\)University of Alberta, Edmonton, AB, \(^2\)Provincial Laboratory for Public Health, Edmonton, AB

---

**Saturday April 18**

**Workshop (1 hour)**

**Break**

**Oral Presentations**

**Moderator:**

Matthew W. Gilmour (Winnipeg, MB)

**Speaker:**

Karen Doucette (Edmonton, AB)

**Objectives:**

At the end of the session, the participant should be able to:

- Identify the treatment options available to various HCV patient populations
- Cite the efficacy, safety and tolerability data of different therapeutic options
- Recognize the expanding treatment armamentarium of HCV

---

**Full Genome Analysis of Enterovirus D-68 Strains Circulating in Alberta, Canada**

K. PABBARAJU\(^1\), S. WONG\(^1\), S.J. DREWS\(^2,3\), G. TIPPLES\(^2,3\), R. TELLIER\(^1,4\)

\(^1\)Alberta Health Services, Provincial Laboratory for Public Health (ProvLab), Calgary, AB, \(^2\)Alberta Health Services, Provincial Laboratory for Public Health (ProvLab), Edmonton, AB, \(^3\)University of Alberta, Edmonton, AB, \(^4\)University of Calgary, Calgary, AB

---

**1100 – 1110 Break**

**1110 – 1125 Oral Presentations (1.25 hour)**

**Session I**

**Room:** Henry (Delta)

---

**1110 – 1125**

**Panel Discussion**

---

**1000 – 1030 Dollars:** Curing HCV-Pay Now or Pay Later?

**Speaker:** Daniel Smyth (Moncton, NB)

**Objectives:**

At the end of the session, the participant should be able to:

- Relate to the health economic impact of untreated HCV
- Identify the potential economic impact of increased treatment using novel HCV regimens
- Demonstrate novel programming being designed to evaluate clinical, epidemiologic, and economic impact in Atlantic Canada
Detection of *Listeria monocytogenes* using Real-Time Amplification Assays

**L. CHIU**1,2, L.M. PATTERSON-FORTIN1, S. CHONG1, J. MAHONY1, F. PAGGOTTO4, M. GRAHAM4, G. VAN DOMSELAAR3, C. BERRY3, N. KNOX1, K. SEYER4, Z. ZHANG4, S. BEKAL5, J. CHEN3, N. PRYSTAJECKY10, P. SLADE11

1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health, Edmonton, AB, 3McMaster University, Hamilton, ON, 4National Microbiology Laboratory, Public Health Agency of Canada, Ottawa, 5National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 6Canadian Food Inspection Agency, St. Hyacinthe, QC, 7Alberta Innovates Technology Futures, Vegreville, AB, 8Laboratoire de Santé publique du Québec, INSPQ, Sainte-Anne-de-Hyacinthe, QC, 9University of British Columbia, Vancouver, BC, 10British Columbia Public Health and Microbiology Reference Laboratory, Vancouver, BC, 11Maple Leaf Foods, Mississauga, ON

Oral Presentations (1.25 hours)

**Session J**

**Moderator:** A. Mark Joffe (Edmonton, AB)

**Oral Presentations**

**1110 – 1225**

**1110 – 1125**

**Immunize Alberta: A Market-Research Based, Targeted, Public Health Immunization Initiative to Combat Vaccine Hesitancy**

**C. CONSTANTINESCU**1,2, V. SAINI1, J. MACDONALD1,2, S. KUHN1,2, D. STRONG1,2, T. JADAVI1,2

1University of Calgary, Calgary, AB, 2Alberta Children's Hospital, Calgary, AB, 3Population and Public Health, Calgary, AB

**1120 – 1225**

**Detection of *Listeria monocytogenes* using Real-Time Amplification Assays**

**L. CHIU**1,2, L.M. PATTERSON-FORTIN1, S. CHONG1, J. MAHONY1, F. PAGGOTTO4, M. GRAHAM4, G. VAN DOMSELAAR3, C. BERRY3, N. KNOX1, K. SEYER4, Z. ZHANG4, S. BEKAL5, J. CHEN3, N. PRYSTAJECKY10, P. SLADE11

1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health, Edmonton, AB, 3McMaster University, Hamilton, ON, 4National Microbiology Laboratory, Public Health Agency of Canada, Ottawa, 5National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 6Canadian Food Inspection Agency, St. Hyacinthe, QC, 7Alberta Innovates Technology Futures, Vegreville, AB, 8Laboratoire de Santé publique du Québec, INSPQ, Sainte-Anne-de-Hyacinthe, QC, 9University of British Columbia, Vancouver, BC, 10British Columbia Public Health and Microbiology Reference Laboratory, Vancouver, BC, 11Maple Leaf Foods, Mississauga, ON

**1110 – 1225**

**1110 – 1225**

**The Special Immunization Clinic Network to Investigate Patients with Adverse Events Following Immunization and Potential Contraindications to Vaccination**

**K.A. TOP**1,2, G. DE SERRES3, M.C. GARIPEY3, S.A. HALPERIN1,2, F.D. BOUCHER4, S. DOBSON4, J.M. PERNICA4, A. PHAM-HUY5, C. QUACH6, D. TRAN7, W. VAUDRY10, S. MCNEIL1,2

1Canadian Center for Vaccinology, IWK Health Centre, Halifax, NS, 2Dalhousie University, Halifax, NS, 3Institut national du santé publique du Québec, Québec, QC, 4Vaccine Evaluation Centre, BC Children’s Hospital, Vancouver, BC, 5McMaster University, Hamilton, ON, 6Children's Hospital of Eastern Ontario, Ottawa, ON, 7Children’s Hospital of Eastern Ontario, Ottawa, ON, 8Montréal Children’s Hospital, Montréal, QC, 9Hospital for Sick Children, Toronto, ON, 10Stollery Children's Hospital, Edmonton, AB

**1140 – 1210**

**Use of Wireless Hand Rub Dispenser Monitoring (eMonitoring) to Improve Hand Hygiene Adherence: a Pilot Study**


Mount Sinai Hospital, Toronto, ON

**1140 – 1155**

**Use of Wireless Hand Rub Dispenser Monitoring (eMonitoring) to Improve Hand Hygiene Adherence: a Pilot Study**


Mount Sinai Hospital, Toronto, ON

**1155 – 1210**

**#Instagram+ID+me: Increasing Student Engagement with An Infectious Diseases Learning Tool on Photography Based Social Media**

**M. WOOD, E. FORGIE, S. FORGIE**

University of Alberta, Edmonton, AB

**1210 – 1225**

**Community-Based Infectious Disease Clinics: A Tool of Engagement for Vulnerable Populations**

**B. CONWAY, S. HAKOBYAN, G. KERKERIAN, S. SHARMA, S. TAHMASEBI, H. TOSSONIAN**

Vancouver Infectious Diseases Centre, Vancouver, BC

**1110 – 1225**

**Oral Presentations**

(1.25 hours)

**Session K**

**Moderator:** Jessica Minion (Regina, SK)

**1110 – 1125**

**PCR Detection of Carbenapenemase-Producing Organisms (CPO) using Cepheid’s Xpert CARBA-R (XCR) Version 1 and 2 Assays**

**B.M. WILLEY3, D.A. BOYD2, G. RICCI3, X. TRIMI4, P. RAHMAN1, D.N. GROHN5, O. LEUNG6, S. DUNNA4, P. LO1, M.R. MULVEY2, T. MAZZULLI1,4, S.M. POUTANEN1,4**

1Mount Sinai Hospital/University Health Network, Toronto, ON, 2National Microbiology Laboratory, Winnipeg, MB, 3University of Calgary, Calgary, AB, 4University of Western Ontario, London, ON, 5National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 6University of Toronto, Toronto, ON, 7Sick Children, Toronto, ON, 8Ontario Ministry of Health and Long-term Care, Toronto, ON, 9Stollery Children's Hospital, Edmonton, AB

**1125 – 1140**

**Comparison of the Abacus Diagnostica Genom Era CDXTM (CDX) PCR and the Focus Diagnostic SimplexaTM Universal Direct C. difficile (FCD) PCR for the Diagnosis of C. difficile Infection (CDI)**

**I. GORN2, E. ADAM1,2, M. DESJARDINS1,2**

1Eastern Ontario Regional Laboratory, Ottawa, ON, 2Ottawa Research Institute, Ottawa, ON, 3University of Ottawa, Ottawa, ON
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>L01</td>
<td>Antibiotic Resistance Surveillance for the Community: Closing the Gap through Public-Private Collaboration in BC</td>
<td>D. PATRICK, D. GEORGE, R. REYES, M. PURCH, M. KELLY</td>
<td>University of British Columbia, Vancouver, BC; British Columbia Centre for Disease Control, Vancouver, BC; LifeLabs Medical Laboratory Services, Burnaby, BC; National Microbiology Laboratory, Winnipeg, MB; Public Health Agency of Canada, Guelph, ON</td>
</tr>
<tr>
<td>L02</td>
<td>Antifungal Susceptibility of Respiratory Aspergillus Isolates from Canadian Hospitals: Results of the CANDWARD 2014 Study.</td>
<td>J. FULLER, S. SHOKOPLES, L. TURNBULL, R.P. RENNIE, H.J. ADAM, M. BAXTER, D.J. HOBAN, G.G. ZHANEL</td>
<td>Provincial Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB; Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB</td>
</tr>
<tr>
<td>L03</td>
<td>Antimicrobial Resistance in Pathogens Isolated from Canadian Hospitals: CANDWARD 2014</td>
<td>M. BAXTER, H.J. ADAM, D. SPREITZER, A. DENISUIK, G. GOLDING, J.A. KARLOWSKY, D.J. HOBAN, G.G. ZHANEL</td>
<td>University of Manitoba, Winnipeg, MB; Diagnostic Services Manitoba, Winnipeg, MB; National Microbiology Laboratory, Winnipeg, MB</td>
</tr>
</tbody>
</table>

**L03 1140-1155**

**L04 1155 – 1210**

Antimicrobial Resistant Organisms in Canada: January 1, 2009 to December 31, 2013

R. MITCHELL, L. PELUDE, S. LEDUC, K. CHOI, K. ABDESSELAM, C. ARCHIBALD, D. GRAVEL, C. FRENETTE

CNISP Participating Hospitals

Public Health Agency of Canada, Ottawa, ON

**L05 1210 – 1225**

Antifungal Susceptibility of Invasive Candida Isolates from Canadian Hospitals: Results of the CANDWARD 2014 Study.


Public Health Agency of Canada, Guelph, ON; University of Manitoba, Winnipeg, MB

**Lunch**

Room: Palmer/Pope (Convention Centre)
DATES: March 30 – April 2 / 30 mars – 2 avril
LOCATION: Sheraton Vancouver Wall Centre
Vancouver, BC
Celebrating 10 years of collaboration Célébrons 10 années de collaboration

**Poster Presentations**

**Thursday April 16 and Friday April 17**
Room: Coles (Convention Centre)

**Poster Viewing:**
Thursday April 16 1100 – 1300
Friday April 17 1100 – 1300

**Presenters at Posters:**
Thursday April 16 1100 – 1230
Friday April 17 1100 – 1230

**Poster Presentations** (P01 – P32)
**Student Poster Presentations** (SP01 – SP49)
**Clinical Vignette Poster Presentations** (CV01 – CV04)
**Innovation Poster Presentations** (IA01 – IA03)

---

**P01**
Antiprotozoal Potential of Phenolic Compounds from *Kleina odora*
N. AL MUSAYEIB1, R. MOOTHANA1, A. EL GAMAL1, S. AL-MASSARANI1, L. AMES2
1King Saud University, Riyadh, Saudi Arabia, 2Antwerp University, Antwerp, Belgium

**P02**
In-vitro Antiviral Action of Amylmetacresol (AMC) and 2,4-Dichlorobenzyl Alcohol (BCDA) Against the Respiratory Pathogen Parainfluenza Type 3
A. SHEPHARD1,2, S. ZYBESHARI1
1Reckitt Benckiser, Slough, UK, 2Society of Biology, London, UK

---

**P03**
Use of Temocillin Resistance (TemR) as a Phenotypic Diffusion Marker for Class D Carbapenemases (Carb) in Carbapenemase-Producing Organisms (CPO)
B.M. WILLEY1, D.N. GROHN2, P. RAHMAN1, D.A. BOYD3, X. TRIMI4, O. LEUNG5, S. DUNNA4, P. LO1, G. RICCI6, T. MAZZULLI1,4, S.M. POUTANEN1,4
1Mount Sinai Hospital/University Health Network, Toronto, ON, 2Michener Institute, Toronto, ON, 3National Microbiology Laboratory, Winnipeg, MB, 4University of Toronto, Toronto, ON, 5University of Western Ontario, London, ON, 6William Osler Health Sciences Centre, Brampton, ON

---

**P04**
Withdrawn

---

**P05**
Novel Isoxetanol Isolated From *Pittosporum tetraspermum* Exhibited Antimicrobial, Antibiofilm and Anticancer Activities
V.A. MARIADHAS, N.A. AL-DHABI
Department of Botany and Microbiology, Addiyah Chair for Environmental Studies, College of Science, King Saud University, Riyadh, Saudi Arabia

---

**P06**
CYP2C19*17 Genetic Polymorphism and Therapeutic Challenges in an Allogeneic Stem Cell Transplant Recipient with Invasive Pulmonary Aspergillosis
M. ABIDI1, A. D’SOUZA1, H. PARMESWARAN1, K. KUPPALLI1
1Medical College of Wisconsin, Milwaukee, WI, USA, 2Loyola University Medical Center, Chicago, IL, USA

---

**P07**
Nanoparticles to Target HIV Reservoirs
C. LAVIGNE1, E. BERGER1, S. STALS1, T. READ2, M.A. LANGLOIS3, D. GONÇALVES4, D. GIRARD5, D. BREZNAN4
1Public Health Agency of Canada, Winnipeg, MB, 2University of Ottawa, Ottawa, ON, 3INRS-Institut Armand-Frappier, Laval, QC, 4Health Canada, Ottawa, ON

---

**P08**
Increased Recovery and Detection of Pathogens Using Copan’s WASPLab™ Total Laboratory Automation (TLA)
M. MCCONNELL1, C. MAIN1,2, W. MCCAFFREY1, D. SKORCHID1, D. YAMAMURA1,2
1Hamilton Health Sciences, Hamilton Regional Microbiology Laboratory, Hamilton, ON, 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON
Usefulness of Previous Methillin-Resistant Staphylococcus aureus Screening Results in Guiding Empiric Therapy for S. aureus Bacteremia

A. BAI1, L. BURRY2, K. SHOWLER1, M. STEINBERG2, D. RICCIUTO4, A. CHIU1, T. RAYBARDHAN2, G. TOMLINSON4,9, C. BELL2,4,10, A. MORRIS2,4,9,10
1University of Ottawa, Ottawa, ON, 2Mount Sinai Hospital, Toronto, ON, 3Leslie Dan Faculty of Pharmacy, Toronto, ON, 4University of Toronto, Toronto, ON, 5Lakeridge Health Partners, Mississauga, ON, 6North York General Hospital, Toronto, ON, 7University Health Network, Toronto, ON, 8Institute for Clinical Evaluative Sciences, Toronto, ON

All-Oral 12-Week Combination Treatment with Daclatasvir (DCV) and Sofosbuvir (SOF) in Patients Infected with HCV Genotype (GT) 3: ALLY-3 Phase 3 Study


1University of Florida, Gainesville, FL, USA, 2Inova Fairfax Hospital, Falls Church, VA, USA, 3Quest Clinical Research, San Francisco, CA, USA, 4Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA, 5Scripps Clinic, La Jolla, CA, USA, 6Atlanta Gastroenterology Associates, Atlanta, GA, USA, 7Kansas City Research Institute, Kansas City, MO, USA, 8Gastro One, Germantown, TN, USA, 9Asheville Gastroenterology Associates, Asheville, NC, USA, 10Texas Clinical Research Institute, Arlington, TX, USA, 11Midland Florida Clinical Research Center, DeLand, FL, USA, 12Mercy Medical Center, Baltimore, MD, USA, 13Fundacion de Investigación de Diego, Buenos Aires, ARG, 14University of Pittsburgh, Pittsburgh, PA, USA, 15Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, NY, USA, 16Medical Associates Research Group, San Diego, CA, USA, 17Southwest CARE Center, Santa Fe, NM, USA, 18Digestive Disease Associates, Baltimore, MD, USA, 19Gastrointestinal Specialists of Georgia, Marietta, GA, USA, 20Premier Medical Group of Hudson Valley, Poughkeepsie, NY, USA, 21Swedish Medical Center, Seattle, WA, USA, 22Bristol-Myers Squibb Research and Development, Princeton, NJ, USA

All-oral, Fixed-dose Combination Therapy with Daclatasvir/Asunaprevir/BMS-791325 for Non-cirrhotic Patients with Chronic HCV Genotype 1 Infection: UNITY-1 Phase 3 SVR12 Results

F. POORDAD2, W. SIEVERT1, L. MOLLISON8, N. BRAINT6, J. LEVIN6, T. SEPE7, S. LEE7, N. BOYER2, J.P. BRONOWICKI2, I.M. JACOBSON10, N. BOPARAI11, E.A. HUGHES13, E.S. SWENSON12, P.D. YIN12

1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA, 2Monash Health and Monash University, Melbourne, Australia, 3Scripps Clinic, La Jolla, CA, USA, 4Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA, 5Scripps Clinic, La Jolla, CA, USA, 6Atlanta Gastroenterology Associates, Atlanta, GA, USA, 7Kansas City Research Institute, Kansas City, MO, USA, 8Gastro One, Germantown, TN, USA, 9Asheville Gastroenterology Associates, Asheville, NC, USA, 10Texas Clinical Research Institute, Arlington, TX, USA, 11Midland Florida Clinical Research Center, DeLand, FL, USA, 12Mercy Medical Center, Baltimore, MD, USA, 13Fundacion de Investigación de Diego, Buenos Aires, ARG, 14University of Pittsburgh, Pittsburgh, PA, USA, 15Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, NY, USA, 16Medical Associates Research Group, San Diego, CA, USA, 17Southwest CARE Center, Santa Fe, NM, USA, 18Digestive Disease Associates, Baltimore, MD, USA, 19Gastrointestinal Specialists of Georgia, Marietta, GA, USA, 20Premier Medical Group of Hudson Valley, Poughkeepsie, NY, USA, 21Swedish Medical Center, Seattle, WA, USA, 22Bristol-Myers Squibb Research and Development, Princeton, NJ, USA

All-Oral, Fixed-dose Combination Therapy with Daclatasvir/Asunaprevir/BMS-791325 for Non-cirrhotic Patients with Chronic HCV Genotype 1 Infection: UNITY-2 Phase 3 SVR12 Results

E.A. HUGHES13, E.S. SWENSON12, P.D. YIN12

1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA, 2Monash Health and Monash University, Melbourne, Australia, 3Scripps Clinic, La Jolla, CA, USA, 4Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA, 5Scripps Clinic, La Jolla, CA, USA, 6Atlanta Gastroenterology Associates, Atlanta, GA, USA, 7Kansas City Research Institute, Kansas City, MO, USA, 8Gastro One, Germantown, TN, USA, 9Asheville Gastroenterology Associates, Asheville, NC, USA, 10Texas Clinical Research Institute, Arlington, TX, USA, 11Midland Florida Clinical Research Center, DeLand, FL, USA, 12Mercy Medical Center, Baltimore, MD, USA, 13Fundacion de Investigación de Diego, Buenos Aires, ARG, 14University of Pittsburgh, Pittsburgh, PA, USA, 15Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, NY, USA, 16Medical Associates Research Group, San Diego, CA, USA, 17Southwest CARE Center, Santa Fe, NM, USA, 18Digestive Disease Associates, Baltimore, MD, USA, 19Gastrointestinal Specialists of Georgia, Marietta, GA, USA, 20Premier Medical Group of Hudson Valley, Poughkeepsie, NY, USA, 21Swedish Medical Center, Seattle, WA, USA, 22Bristol-Myers Squibb Research and Development, Princeton, NJ, USA

Recurrent Micafungin-Resistant Candida glabrata Candidemia with Prolonged Micafungin Treatment for Multiple Intra-abdominal Abscesses: A Case Report

H.Y. ZHOU1, S. SHOKOPLES1, B. JANSEN2, J. FULLER1
1Alberta Health Service, Edmonton, AB, 2University of Alberta, Edmonton, AB

Active Environmental Surveillance of Lyme Disease in British Columbia (2013 and 2014)

M.K. LEE1, K. FERNANDO1, S. MAN1, K. JENS1, B. KAHNAMELLI1, D. TAM1, T. DHANO1, Q. WONG7, P. TANG1, D. PATRICK2, S. MA1, A. HOJGAARD4, B. HENRY5, M. MORSHED2, 1

1BC Public Health Microbiology and Reference Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC, 3Centre for Disease Control and Prevention, Fort Collins, CO, USA, 4BC Ministry of Health, Vancouver, BC

Investigating the Potential Role of Bacterial Infection in Granulomatosis with Polyangiitis (GPA)

R. FATTOUH1, B.M. WILLEY2, J.V. KUS1, T. MAZZULLI2, 1

1University of Toronto, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON, 3Public Health Ontario Laboratories, Toronto, ON

Evaluation of Antigen Detection for Confirmatory Testing of Hepatitis C Virus Infection

P.N. LEVETT1, D. CASWELL1, J. PUTZ1, N. MINA1, J. C. EICHHORST1, G.B. HORSMAN1

1Saskatchewan Disease Control Laboratory, Regina, SK
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>P18</td>
<td>Recurrent Invasive <em>Haemophilus influenzae</em> Type a Infection in an Infant</td>
<td>K. Whyte, P.N. Levet, G.B. Horsman, K. Chokani, K. Hayden, M. Shuel, R.S.W. Tsang</td>
<td>Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Winnipeg, MB, Saskatchewan Disease Control Laboratory, Regina, SK, Prince Albert Parkland Health Region, Prince Albert, SK</td>
</tr>
<tr>
<td>P19</td>
<td>Optimizing the Diagnostic Yield of Joint Fluid/Tissue Culture for the Hamilton Regional Laboratory Medicine Program</td>
<td>M. Rehan, C. Main</td>
<td>McMaster University and Hamilton Regional Laboratory Medicine Program, Hamilton, ON</td>
</tr>
<tr>
<td>P20</td>
<td>Pushing the Limits of Chemistry Point-of-Care Testing for the Management of Patients under Investigation for Ebola Virus Disease</td>
<td>J. Leflad, C. Heinstein, J. Macdonald, R. Gallant, C. Roberts, A. Lou, B. Nassar</td>
<td>Capital District Health Authority, Halifax, NS, Department of Pathology and Laboratory Medicine, Dalhousie University, Halifax, NS</td>
</tr>
<tr>
<td>P21</td>
<td>Increase in Methicillin-susceptible <em>Staphylococcus aureus</em> with Reduced Susceptibility to Triclosan Over the Last 20 Years</td>
<td>M. Kisson, T. Ramdass, M. Seyed Saleh, A. Khan, B. Frame, B.M. Willey, D.E. Low, S.M. Poutanen</td>
<td>University of Toronto, Toronto, ON, University Health Network / Mount Sinai Hospital, Toronto, ON</td>
</tr>
<tr>
<td>P22</td>
<td>Characterizing the Resistance Related Mutations in the NS3 Protease of Hepatitis C-Infected Ontario Patients</td>
<td>T. Mazzulli, S. Persunski, J. Mareamen, O. Woods, A. Li</td>
<td>Public Health Laboratories, Public Health Ontario, Toronto, ON, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Mount Sinai Hospital/University Health Network, Toronto, ON</td>
</tr>
<tr>
<td>P23</td>
<td>Iron Restriction to Clinical Isolates of <em>Candida albicans</em> by DIBI Inhibits Growth and Increases Sensitivity to Azole Antifungals</td>
<td>K. Savage, M. Parquet, D. Allan, R. Davidson, B. Holbein</td>
<td>Chelation Partners Inc., Halifax, NS, Capital District Health Association, QEII Health Sciences Centre, Halifax, NS, Department of Microbiology and Immunology, Dalhousie University, Halifax, NS</td>
</tr>
<tr>
<td>P24</td>
<td>Withdrawn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P25</td>
<td>SNAP—Sepsis Now a Priority: Development and Implementation of a Sepsis Algorithm in the Emergency Department of an Academic Hospital</td>
<td>S. West, M. Morgan, D. Dushenski, C. Macdonald, K. Van den Broek, A. Morris, S. Lapinsky</td>
<td>Mt. Sinai Hospital, Toronto, ON, University Health Network, Toronto, ON, Department of Medicine, University of Toronto, Toronto, ON</td>
</tr>
<tr>
<td>P26</td>
<td>What a Fluke: A Case of Biliary Fascioliasis in a Recent Immigrant</td>
<td>V. Meier-Stephenson, T. Ishikawa, S. Vaughan, S. Bass, S. Heitman, D. Gregson</td>
<td>Division of Infectious Disease, Department of Medicine, University of Calgary/Alberta Health Services, Calgary, AB, Division of Gastroenterology, Department of Medicine, University of Calgary/Alberta Health Services, Calgary, AB, Medical Microbiology, Calgary Laboratory Services, Calgary, AB</td>
</tr>
<tr>
<td>P27</td>
<td>AMR, Public Health, and Knowledge Translation: A Forward Approach</td>
<td>J. Kettner, M. Haworth-Brockman, S. Balakumar, B. Muzzulli, B. Holbein</td>
<td>National Collaborating Centre for Infectious Diseases, Winnipeg, MB, International Centre for Infectious Diseases, Winnipeg, MB, University of Manitoba College of Medicine, Winnipeg, MB, University of Winnipeg, Winnipeg, MB</td>
</tr>
<tr>
<td>P28</td>
<td>Oversight of Human and Animal Pathogens and Toxins</td>
<td>M. L. Graham</td>
<td>Public Health Agency of Canada, Ottawa, ON</td>
</tr>
<tr>
<td>P29</td>
<td>Withdrawn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P30</td>
<td>The Retrospective Study of the Prevalence and Clinical Significance of Hepatitis B Virus Precore and Basal Core Promoter Variants</td>
<td>K. Kadkhoda, M. O’Brien, A. Casseman, G. Smart, A. Gretchen, K. Kaita</td>
<td>Cadham Provincial Laboratory, Winnipeg, MB, Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, PGME, University of Manitoba, Winnipeg, MB, Viral Hepatitis Investigative Unit at the Health Sciences Centre, University of Manitoba, Winnipeg, MB</td>
</tr>
<tr>
<td>P31</td>
<td>Mycoplasma pneumoniae Infection in Children Less Than Five Years of Age; a 17 Years Review</td>
<td>R. Adwan, A. Bitnun, A.Y. Shen, Y. Aua, S. Richardson</td>
<td>The Hospital for Sick Children, Toronto, ON, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, University of Toronto, Toronto, ON, Department of Paediatrics, King Abdul-Aziz Medical City, Jeddah, Kingdom of Saudi Arabia</td>
</tr>
<tr>
<td>P32</td>
<td>Emergency Department Utilization of Respiratory Virus Testing for Febrile Young Infants Under Six Weeks of Age</td>
<td>B. Burstein, A.S. Dubrovsky, A. Greene, C. Quach</td>
<td>Montréal Children’s Hospital, Department of Pediatric Emergency Medicine, Montréal, QC, Montréal Children’s Hospital, Department of Pediatric Infectious Diseases, Montréal, QC, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montréal, QC</td>
</tr>
</tbody>
</table>

*P18* to *P32* are page numbers from the document.
Celebrating 10 years of collaboration Célébrons 10 années de collaboration

**Student Poster Presentations**

**SP01**
COPD Symptom and Disease Screening in an HIV Population
B. GHADAKI1, N. KRONFLI1, S. HAIDER1,2
1McMaster University, Hamilton, ON, 2Division of Infectious Diseases, Hamilton Health Sciences, Hamilton, ON

**SP02**
Withdrawn

**SP03**
Characterization of Canadian Hospital Infection Control Practices for Caregivers and Visitors
G. CHAN1, G. VOMIERO2, J.V. VAYALUMKAL2
1University College Dublin, Dublin, Ireland, 2Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB

**SP04**
Antimicrobial Prescribing Practices in the Treatment of Suspected UTI in the Elderly in the Emergency Department: a Retrospective Single Centre Study
C. LATA1, R. SOMAYAJI1,2, D.L. HOLTON2
1University of Calgary Department of Internal Medicine, Calgary, AB, 2Department of Infectious Diseases, Calgary, AB

**SP05**
The Infectiousness and/or Virulence of Isoniazid-Resistant vs. Susceptible Pulmonary Tuberculosis: A Case-Control Study in Alberta
H.Y. ZHOU1,2, D. LONG1, Z. GAO1, S. CHRISTIANSON2, M. SHARMA2, J. WOLFE2, C. HEFFERNAN1, R. LONG1
1University of Alberta, Edmonton, AB, 2National Reference Center for Mycobacteriology, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 3The Provincial Laboratory for Public Health, Edmonton, AB

**SP06**
Meropenem MIC Profile of Carbapenemase-Producing Enterobacteriaceae in a Low Prevalence Region
R. FATTOUH1, N. TIJET1, A.J. MCGEER1,3, S.M. POUTANEN1,3, R.G. MELANO1,2, S.N. PATEL1,2
1University of Toronto, Toronto, ON, 2Public Health Ontario Laboratories, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON

**SP07**
Creation of a Novel Pediatric Antimicrobial Stewardship Advanced Fellowship Training Program
N. RAJAPAKSE1,2, J.V. VAYALUMKAL1,2,3, L. BRESEE1,2, B. DALTON1,2, T. JADAVJI1,2, C. TSANG1,2, O. VANDERKOOI1,2, J. CONLY1,2
1University of Calgary, Calgary, AB, 2Infection Prevention and Control, Alberta Health Services, Calgary, AB, 3Alberta Children's Hospital, Calgary, AB

**SP08**
Emerging Antimicrobial Resistance among Staphylococcus pseudintermedius, a Potential Zoonoses of Canine Origin
R. PRIYANTRA, J. RUBIN
University of Saskatchewan, Saskatoon, SK

**SP09**
Positive Impact of Infectious Disease Consultation on Quality of Care, Mortality and Length of Stay in Staphylococcus aureus Bacteremia: Results from a Large Multicenter Cohort Study
A. BA1, A. SHOWLIER2, L. BURRY3,4, M. STEINBERG1, D. RICCIUTO2,3, T. FERNANDES1,2, A. CHIU1, S. RAYBARDHAN2, M. SCIENCE3, E. FERNANDO2, G. TOMLINSON2, C. BELL1,2, A. MORRIS3,9
1North York General Hospital, Toronto, ON, 2University of Toronto, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON, 4Leslie Dan Faculty of Pharmacy, Toronto, ON, 5Lakeridge Health, Oshawa, ON, 6Trillium Health Partners, Mississauga, ON, 7North York General Hospital, Toronto, ON, 8Hospital for Sick Children, Toronto, ON, 9University Health Network, Toronto, ON, 10Institute for Clinical Evaluative Sciences, Toronto, ON

**SP10**
Prospective Observational Study of Diagnosis of Urinary Tract Infection and Response to Therapy in Long Term Care Facilities
C. PENNEY1, S. WAKEHAM1, G. COMPTON2, A. MCKIM2, J. O’KEEFE2, B. BARRETT2, L. NICOLLE2, P. DAILY1
1Memorial University, St. John’s, NL, 2Eastern Health Region, St. John’s, NL

**SP11**
Molecular Epidemiology of Vancomycin Heteroresistant Coagulase-Negative Staphylococci in a Neonatal Intensive Care Unit in Québec
J. CHONG1, S. LÉVESQUE1, A. BLANCHARD1, C. LAFFERRIERE1, C. QUACH1,4
1McGill University, Montréal, QC, 2Laboratoire de santé publique du Québec/Institut national de santé publique du Québec, Montréal, QC, 3CHU St Justine Hospital, Montréal, QC, 4Montréal Children’s Hospital, Montréal, QC

**SP12**
Increasing Incidence of Group C and Group G Streptococcal Bacteremia Attributed to Increased Bacterial Virulence Factors and Poor Outcomes
S. LOTHER1, Y. KEYNAN1,2, P. DEGAGNE3, P. LAGACÉ-WIENS2,5, M.R. MULVEY2,4, I. MARTIN1
1University of Manitoba, Department of Internal Medicine, Winnipeg, MB, 2University of Manitoba, Department of Medical Microbiology and Infectious Disease, Winnipeg, MB, 3Diagnostix Services Manitoba, Winnipeg, MB, 4National Microbiology Laboratory, Winnipeg, MB

**SP13**
Antimicrobial Stewardship in Primary Care: An Evaluation of the Management of Acute Uncomplicated Cystitis in a Family Health Team
M. ROSTOM1, P. MARR1,2, D. KWAN1,2, C. PAPOUSHEK1,2, L. DRESSER1,2, C. LEMIEUX1,2
1University Health Network, Toronto, ON, 2University of Toronto, Toronto, ON

**SP14**
Withdrawn

**SP15**
Clostridium difficile Infections (CDI) in Children: Are we Overestimating Rates just Because of the Diagnostic Method Used?
M. ALGHOUNAIM, Y. LONGTIN, M. GONZALES, M. BILHETE, C. QUACH
McGill University, Montréal, QC
Celebrating 10 years of collaboration

Célébrons 10 années de collaboration

SP29
A. DENISUIK1, H.J. ADAM1,2, P. LAGACE-WIENS1,2, P. SIMNER2, M.R. MULVEY1,2, M. BAXTER1, M. GILMOUR1,2, J.A. KARLOWSKY1,2, D.J. HOBAN1,2, G.G. ZHANEL1
1University of Manitoba, Winnipeg, MB, 2Diagnostic Services Manitoba, Winnipeg, MB, 3National Microbiology Laboratory, Winnipeg, MB

SP30
Inpatient Care of Community Acquired Pneumonia: Opportunities for Improvement
S. DE L’ÉTOILE-MOREL1, H. BA TAHER2, E.G. MCDONALD, T.C. LEE
McGill University, Montréal, QC

SP31
Feasibility of UV-C Light Disinfection in a Canadian Hospital
Y. EMOND1, I. DEANS2, C. O’NEILL2, D. MERTZ1,2
1McMaster University, Hamilton, ON, 2Hamilton Health Sciences, Hamilton, ON

SP32
Non-Polio Enterovirus Types Associated with Acute Flaccid Paralysis – A Systematic Review
S. SURESH1, J. ROBINSON1, S. FORGIE1
University of Alberta, Edmonton, AB

SP33
Evaluation of Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) for Yeast Identification
S. MASUD1, D. ROSCOE1,2
1University of British Columbia, Vancouver, BC, 2Vancouver Coastal Health Authority, Vancouver, BC

SP34
Xpert MTB/RIF as a Supplemental Test to Acid-Fast Bacilli Sputum Microscopy in the Diagnosis of Tuberculosis: Potential Resource Savings
P. DOYLE1,2, T. WONG1,2, D. ROSCOE1,2, E. CONNOLLY1,2, E. KOECK5
1Vancouver General Hospital, Vancouver, BC, 2University of British Columbia, Vancouver, BC

SP35
Hospitalized Influenza Patients during 2013-2014: a Comparison of ICU and Ward Treated Patients including Antimicrobial Therapy, Adverse Events, and Outcomes
A. MCFARLANE1, S. SMITH, W. SLIGL, L. SAXINGER
University of Alberta, Edmonton, AB

SP36
Clinical Spectrum of Rhinovirus Infections in Hospitalized Children in Israel - A Single Center’s Experience
G. POMERANZ1, E. MENDELSON1,2, M. MANDELBOIM3,4
1Schneider Children’s Medical Center of Israel, Petah Tikva, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3Chaim Sheba medical Center, Tel Hashomer, Ramat-Gan, Israel

SP37
Prosthetic Joint Infections: Patterns of Practice for Diagnosis, Management, and Outcome
D. HARRIS1, J. DE BEER1, M. WINEMAKER2, D. PETRUCCELLI1, D. MERTZ1
McMaster University, Hamilton, ON

SP38
Urinary Biomarkers in Patients with Cystic Fibrosis
E. VALLIERES1, G. PAREKH1, M.M. TUNNEY1, G. EINARSSON1, S. MCGRATH1, L. MCLIRAVEY1, E. JOHNSTONE1, K. WOOLSTON2, D. DOWNEY1, P. DAVIS2, J.S. ELBORN1
1Queen’s University Belfast, Cystic Fibrosis and Airways Microbiology Research Group, Belfast, UK, 2Mologic Ltd., Bedford, UK

SP39
Carbon Source Modulates Paradoxical Growth Effect of Caspofungin in *Candida albicans*
A. DELORME1, R. P. RENNIE1,2
1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health, Edmonton, AB

SP40
Cost-effectiveness of MALDI-TOF MS in Clinical Analysis of Urine Specimens in Nova Scotia
H. AL SIDAIR1,2, T. HATCHETTE1,2, D. HALDANE1,2, R. DAVIDSON1,2
1Dalhousie University, Halifax, NS, 2Queen Elizabeth II Health Sciences Centre, Halifax, NS

SP41
Role of Type IV Pili in the *Clostridium difficile* Pathogenic Program
C. MARTINEZ DE LA PENA1, Y. LI1, G. MALDARELLI1, G. ARMSTRONG1, M. DONNENBERG3
1University of Calgary, Faculty of Medicine, Calgary, AB, 2University of Maryland, School of Medicine, Baltimore, MD, USA

SP42
Detection and Characterization of a 2014 *Escherichia coli* O157:H7 Outbreak in Alberta by Multiple Molecular Methods Including Whole Genome Sequencing
B. BERENGER1,2, C. BERRY3, C. NADON4, L. TSCHETTER5, P. FACK3, S. DELANNYO5, V. LI1, T. PETERSON1, L. CHUI1,2
1Alberta Provincial Laboratory for Public Health, 2University of Alberta Department of Medical Microbiology and Immunology, 3University of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, AB, 4Public Health Agency of Canada National Microbiology Laboratory, Winnipeg, MB, 5Food Safety Laboratory, Maisons-Alfort, France

SP43
Heat Resistant Shiga Toxin-Producing *Escherichia coli* (STEC) from Clinical Cases in Alberta
A. MA1, L.M. PATTERSON-FORTIN1, L. CHUI1,2
1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health, Edmonton, AB

SP44
The Use of Antibiotics in the Treatment of Skin and Soft Tissue Infections in Selected First Nations Communities
D. JEONG1, Y. SCHREIBER2, M. TYNDALL1,2
1University of Ottawa, Ottawa, ON, 2The Ottawa Hospital, Ottawa, ON, 3Ottawa Hospital Research Institute, Ottawa, ON

SP45
The Role of Inter-Hospital Sample Transport in Total Assay Time for Microbiological Screening Tests
A. LAWANDI1, T.C. LEE1,2, C. FRENNETE2
1Department of Medicine, Division of Internal Medicine, McGill University Health Centre, Montréal, QC, 2Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, QC
Investigation of Matrix Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) for Detection of *Clostridium difficile* Toxin A and B from Stool Samples

C. LAM1, A. MCCLEAN1, E. KOECK1, L. ANG2, P. NAIDU3, K. DONKOR4, K. WAGNER5, N. CHEEPHAM1

1Department of Biological Sciences, Faculty of Science, Thompson Rivers University, Kamloops, BC, 2Microbiology Laboratory, Royal University Hospital, Saskatoon, SK, 3Provincial Laboratory for Public Health, University of Alberta, Edmonton, AB, 4Department of Physical Sciences, Faculty of Science, Thompson Rivers University, Kamloops, BC

Cumulative Antimicrobial Susceptibility Data from ICUs at One Institution: Should Data be Combined?

A. CAMPIGOTTO1, M. MULLER1,2, L. R. TAGGART1,2, R. HAJ3, E. LEUNG3, J. NADARAJAH1,2, L.M. MATUKAS1,2

1University of Toronto, Toronto, ON, 2St. Michael’s Hospital, Toronto, ON

Infectious Complications after Central Venous Catheter Repair in Pediatric Patients

G. SHAH, B. LEE, J. DURAND, N. GARTNER, S. FORGIE

University of Alberta, Edmonton, AB

Acute Odontogenic Infection Management in the OPAT Clinic Setting: a Quality Improvement Study in Calgary, Alberta

W.J. CONNORS, M.D. PARKINS, D.L. HOLTON

University of Calgary, Calgary, AB

**Clinical Vignette Posters**

**CV01**

Adenovirus Interstitial Nephritis in a Patient with Renal Transplant

S. ALA

Miami Valley Hospital, Dayton, OH, USA, Department of Medicine, Wright State University, Dayton, OH, USA

**CV02**

A Case of *Capnocytophaga canimorsus* Meningitis

G. PATRIQUIN1, S. MCNEIL2

1Department of Medicine, Dalhousie University, Halifax, NS, 2Division of Infectious Diseases, Department of Medicine, Dalhousie University, Halifax, NS

**CV03**

Withdrawn

**CV04**

Atypical Case of Atypical Pneumonia: Disseminated *Mycoplasma hominis* Infection in a Double Lung Transplant Recipient

A. MAH1, T. WONG2, L. HOANG3, A. STEFANOVIC2

1Division of Infectious Diseases, University of British Columbia, Vancouver, BC, 2Division of Medical Microbiology, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, 3BCCDC Public Health Microbiology & Reference Laboratory, Provincial Health Services Authority, Vancouver, BC

**Internet Café**

Thursday April 16 to Saturday April 18

ROOM: Main Foyer (Delta Prince Edward)

Hours:

Thursday April 16: 0700 – 1730

Friday April 17: 0700 – 1730

Saturday April 18: 0700 – 1730
Author Index

A
Abdesselam K .................................................. L04
Abidi M .................................................. P06
Adam E .................................................. K02
Adam H .................................................. D02,L02,L03, L05,SP29
Adomako K .................................................. E06
Adumattah A .................................................. SP28
Adwan R .................................................. P31
Al-Busaidi I .................................................. SP27
Al-Dhabi NA .................................................. P05
Al-Mansouri W .................................................. P31
Al-Massarani S .................................................. P01
Al-Musayeb N .................................................. P01
Al Mutawa F .................................................. K03
Al Sidairi H .................................................. SP40
Ala S .................................................. CV01
Alghounaim M .................................................. SP15
Allan D .................................................. P23
Allison D .................................................. H02
Ames L .................................................. P01
Andonova M .................................................. F04
Ang J .................................................. SP46
Archibald C .................................................. L04
Armstrong G .................................................. SP19,SP41
Ash T .................................................. B02
Asztalos E .................................................. E03

B
Ba Taher H .................................................. SP30
Bai A .................................................. P09,SP09
Bajgai J .................................................. H02
Balakumar S .................................................. P27
Barber D .................................................. SP19
Barrett B .................................................. SP10
Barth C .................................................. A02
Barton M .................................................. A03
Bass S .................................................. P26
Baxter M .................................................. D02,L02,L03, L05,SP29
Beaudry G .................................................. I03
Bekal S .................................................. I03,IO5
Bell C .................................................. P09,SP09

Bennett M .................................................. P11
Berenger B .................................................. SP42
Berger E .................................................. P07
Bergeron L .................................................. SP20,IA01
Bernard K .................................................. B04
Bernatchez H .................................................. IA01
Bernstein D .................................................. P11
Berry C .................................................. I03,IO5,SP42
Bilhete M .................................................. SP15
Bitnun A .................................................. P31
Blanchard A .................................................. SP11
Blondel-Hill E .................................................. D04
Boikos C .................................................. F03,SP18
Boivin A .................................................. IA01
Booth T .................................................. F05
Boparai N .................................................. P12
Borgundvaag B .................................................. SP26
Boswell J .................................................. E02
Boucher FD .................................................. J02,SP18
Boyd DA .................................................. K01,K05,P03
Boyer N .................................................. P12
Brau N .................................................. P12
Breese L .................................................. SP07
Brezan D .................................................. P07
Bronowicki J-P .................................................. P12
Brooks A .................................................. P10
Burdz T .................................................. B04
Burry L .................................................. P09,SP09
Burstein B .................................................. P32

Callery S .................................................. E01
Campigotto A .................................................. SP47
Casselman A .................................................. P30
Caswell D .................................................. P17
Catt B .................................................. E01
Chagla Z .................................................. SP22
Chahil N .................................................. F01
Chan G .................................................. SP03
Chapman W .................................................. G05
Charest H .................................................. F03
Cheeptham N .................................................. SP46

Chen J .................................................. I05
Chen Y .................................................. SP24
Chilvers M .................................................. SP18
Chiu A .................................................. P09,SP09
Cho P .................................................. E01
Choi K .................................................. L04
Chokani K .................................................. P18
Chong J .................................................. SP11
Chong M .................................................. D04
Chong P .................................................. B01
Chong S .................................................. I05
Christianson S .................................................. C02,SP05
Chu K .................................................. F01
Chui L .................................................. A03,I02,I05,SP42,SP43
Chuin S .................................................. CV03
Chuu S .................................................. E02
Clark S .................................................. C04
Coburn B .................................................. C04
Cohen A .................................................. J03
Cole J .................................................. A04
Colemand B .................................................. SP26
Compton G .................................................. SP10
Conly J .................................................. SP07,SP19
Connolly E .................................................. SP34
Connors WJ .................................................. SP49
Constantinescu C .................................................. J01
Conway B .................................................. J05
Cook P .................................................. H01
Cook W .................................................. E02
Cooper JN .................................................. P11
Corpus C .................................................. E01
Craig J .................................................. SP27

D
D’Souza A .................................................. P06
Daigneault P .................................................. SP18
Daku D .................................................. A02
Daley P .................................................. A04,H02,SP10
Dalton B .................................................. SP07
Davidson R .................................................. P23,SP40
Davies HD .................................................. E03
Davis P .................................................. SP38
De Beer J .................................................. SP37
De L’Étoile-Morel S .................................................. SP30
De Repentigny L .................................................. E03
De Serres G .................................................. J02
Deans I .................................................. SP31
Degagne P .................................................. SP12
Delannoy S .................................................. SP42
Delorme A .................................................. SP39
Delport J .................................................. B03
Demczuk W .................................................. D02
Denisulk A .................................................. L03,SP29
Deserres G .................................................. F03
Desjardins M .................................................. B04,K02
Dhanoa T .................................................. P15
Díaz Caballero J .................................................. C04
Díaz-Mitoma F .................................................. IA03
Dimitrova K .................................................. F04
Dionne M .................................................. SP20
Dobson S .................................................. J02
Dolc P .................................................. IA01
Donaldson S .................................................. C04
Donkor K .................................................. SP46
Donnenberg M .................................................. SP41
Dore GJ .................................................. P13
Doualla-Bell F .................................................. I03
Doucette K .................................................. SP17
Downey D .................................................. SP38
Downing M .................................................. G05
Doyle P .................................................. SP34
Drebot M .................................................. F04
Dresser L .................................................. SP13
Drew T .................................................. B01,D03
Drews SJ .................................................. F05, I01, SP16
Dubrovsky AS .................................................. P32
Dunna S .................................................. G01,G04,K01,K05,P03
Durand J .................................................. SP48
Dushenski D .................................................. P25
Dust K .................................................. F05
Duvvuri VR .................................................. F02
R
Rafat Gad R.................................A01
Rabinovitz M..................................P11
Radko S............................................F06
Rahman P..................................G10,04,K01,K05,P03
Rajapakse N.................................SP07
Ramdass........................................P21
Ranji A............................................P13
Rana K............................................P11
Ravendhran N.................................P11
Ray bastard S.................................P09,SP09
Read T............................................P07
Rehan M............................................P19
Reimer A...........................................I03
Rennie RP........................................L02,L05,SP39
Reyes R............................................L01
Ricci G............................K01,K05,P03
Ricciuto D..............................P09,SP09,SP28
Richardson S................................E03,F05,P31
Roberts C........................................P20
Robertson J.................................E06,E03,SP32
Rodrigues M....................................C03
Roscoe D..................................SP33,SP34
Rosenfeld P.................................F02
Rostom M.................................SP13
Rubin E............................................E03
Rubin J............................................SP08
Rutherford C..............................F05,G03,H03,IA02
Ryan L............................................SP28
S
Saini V...........................................J01
Saltzman I........................................SP27
Saúde R............................................E03
Savage K........................................P23
Saxinger L.......................................SP35
Scheiffele D.................................F03
Scheiffele G....................................SP18
Schleihau E....................................I04
Schreiber Y.................................SP44
Science M.....................................SP09
Scott AN........................................SP16
Sepe T............................................P12
Seyed Salehi M...............................P21
Seyer K............................................I05
Shah G............................................SP48
Sharma M........................................C02,SP05
Sharma S........................................J05
Sheikh AM.......................................P11
Shen A............................................P31
Shen YH..........................................E03
Shephard A......................................P02
Shokoples S.................................L02,L05,P14
Showler A.......................................SP09
Shuel M...........................................D03,P18
Shumilak G......................................SP23
Sievert W.......................................P12
Simmonds K....................................SP16
Simmer P.........................................SP29
Simor A...........................................E01,SP24
Simpson K.......................................E03
Simpson Y........................................F01
Skorcid D........................................P08
Slade P.............................................I05
Sigl W.............................................SP35
Smart G...........................................P30
Smieja M..........................F05,G06,IA02
Smith S............................................SP17,SP35
Smyth D.........................................SP25
So J...............................................J03
Sohrabi M.......................................H04
Somayaji R.................................SP04
Spreitzer D.................................L03
Stals S.............................................P07
Steenhoff AP.................................G06
Steinberg M.................................P09,SP09
Stewart S.........................................SP23
Stordal K.........................................G06
Strikwerda A....................................B03
Strong D.........................................J01
Stuart J.............................................F06
Suresh S.........................................SP32
Swenson ES.................................P12,P13
Synnes A.........................................E03
T
Taggart LR.....................................SP47
Tahmasebi S....................................J05
Tam D.............................................P15
Tambalo D......................................SP19
Tan B.............................................E03
Top KA............................................J02
Tossonian H.....................................J05
Tran A.............................................P13
Tran D.............................................J02
Tremblay C.....................................I03
Trimi X...........................................G01,G04,K01,K05,P03
Trout-Yakel K.................................B01
Tsang C...........................................SP07
Tsang RSW.................................D01,D03,P18
Tscherter L......................................SP42
Tullis DE..........................................C04
Turney MM.......................................SP38
Turrene CY.................................B02
Turnbull L.................................L02,L05
Tyndall M.......................................SP44
U
Ulanoa M.....................................D01
V
Valan Arasu M.................................P05
Valiieres E.......................................SP38
Van Den Broek K..............................P25
Van Domselaar G.............................I05
Vanderkooi O.................................SP07
Varunok P........................................P11
Vaudry W.......................................J02
Vaughan S.......................................P26
Vayalumkal JV.................................SP03,SP07
Veercombe M...............................E01
Vommiero G....................................SP03
W
Wagner K......................................SP46
Wakeham S......................................SP10
Wang P.............................................C04
Waters V.........................................C04
Wayment L......................................J03
Webster D.................................H01
Wells K...........................................A04
West S............................................P25
Westmacott G.................................B01
Whellams D.................................SP22
Whitney H......................................H02
Whyte K.........................................D03,P18
Wiebe D..........................................B04
Wilcox T.........................................SP25
Wilcock D.......................................J03
Willey B..........................................P16
Willey BM.................................G01,G04,K01,K05
........................................P16,P03,P21
Williams K....................................SP23
Winemaker M.................................SP37
Wolfe J...........................................C02,SP05
Wong B...........................................E01
Wong F...........................................E01
Wong J.............................................J03
Wong Q.............................................F01,H06,P15
Wong S.............................................I01
Wong T...........................................SP34
Wood M.........................................J04
Woods O.................................P22
Woolston K.....................................SP38
Wu K.............................................SP19
X
Xiong J..........................................G05
Y
Yamamura D.................................H03,P08
Yang R.............................................P13
Yau Y.............................................C04,E03,P31
Ybazaeta G.................................IA03
Yin PD..........................................P12,P13
Yirenkyi A.......................................J03
Younes ZH....................................P11
Yu N..............................................C02
Z
Zahariadis G.................................F06
Zelyas N........................................SP17
Zhanel G.................................D02,L02,L03,IO5,SP29
Zhang J...........................................I05,SP19
Zhang K.........................................SP19
Zhang L..........................................J03
Zhang Y..........................................C04
Zhou HY.........................................P14,SP05
Zybeshari A...................................P02

Celebrating 10 years of collaboration
Célébrons 10 années de collaboration
## Conflict of Interest

<table>
<thead>
<tr>
<th><strong>Committee Member / Speaker</strong></th>
<th><strong>Disclosure</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam, Heather</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Barnes, Penny</td>
<td>Received grants or honoraria from Hoffman-LaRoche Ltd: advisory board for HER2 testing.</td>
</tr>
<tr>
<td>Barrett, Lisa</td>
<td>Member of an Advisory Board or equivalent with AbbVie and Gilead, received grant(s) or an honorarium from AbbVie, and currently participating in or have participated in a clinical trial within the past 2 years with Gilead.</td>
</tr>
<tr>
<td>Blondel-Hill, Edith</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Chan, Adrienne</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Chiu, Isabelle</td>
<td>Member of an Advisory Board or equivalent with Janssen, Merck, Pfizer, and Sunovion, member of a Speakers bureau with Merck and Sunovion, received payment from a commercial organization (including gifts or other consideration or ‘in kind’ compensation) from Janssen, Merck, Pfizer, and Sunovion, received grants or an honorarium from Janssen, Merck, Pfizer, and Sunovion, and currently participating in or have participated in a clinical trial within the past 2 years via the University of Alberta Division of ID Clinical Trials (no direct financial transactions).</td>
</tr>
<tr>
<td>Conly, John</td>
<td>Member of an Advisory Board or equivalent with Merck/Cubist and received an honorarium and funding from bioMérieux and Pfizer to attend a meeting as a speaker on antibiotic resistance. Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).</td>
</tr>
<tr>
<td>Daley, Peter</td>
<td>Received grants or honoraria from Copan USA for research project funding in June 2011 for $13,500 and currently participating in or have participated in a clinical trial within the past 2 years with Cubist for LCD-CDAD-11-06.</td>
</tr>
<tr>
<td>Dey, Meghan</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Doucette, Karen</td>
<td>Received a speaking honorarium from Gilead and Roche and currently participating in or have participated in a clinical trial within the past 2 years with BMS, Gilead, AbbVie, Merck, and Janssen. Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).</td>
</tr>
<tr>
<td>Evans, Gerald</td>
<td>Currently participating in or has participated in a clinical trial within the past 2 years with Merck for a CDI study, Astellas for an Isavuconazole study, and Biocryst for a peramivir study.</td>
</tr>
<tr>
<td>Falzarano, Darryl</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Forgie, Sarah</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Fuller, Jeff</td>
<td>Member of an Advisory Board or equivalent with Sunovion and Merck, received payment (including gifts or other consideration or ‘in kind’ compensation) from Sunovion and Merck, and received a grant(s) or an honorarium from Astellas.</td>
</tr>
<tr>
<td>German, Greg</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Gilmour, Matthew</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Gregson, Daniel B.</td>
<td>Received a grant for antibiotic resistance research from Merck, a grant for research of antibiotic resistance and organism detection using BD Max assay from BD Diagnostics, received a grant for rapid identification of organisms in blood cultures (in planning process) from BioMérieux; and is currently participating in or have participated in a clinical trial within the past 2 years with Merck, BD Diagnostics, and BioMérieux.</td>
</tr>
<tr>
<td>Haider, Shariq</td>
<td>Member of an Advisory Board or equivalent with Pfizer, Merck, and Astellas for the past 2 years and currently participating in phase 1, 2, and 3 clinical trials with Merck.</td>
</tr>
<tr>
<td>Hatchette, Todd</td>
<td>Received grants or an honorarium from GSK on an investigator driven grant titled &quot;Sentinel surveillance for influenza requiring hospital admissions in Canadian Adults&quot; as part of a collaborative research agreement; and on a collaborative project using a novel vaccine delivery system for influenza vaccine.</td>
</tr>
<tr>
<td>Joffe, Mark</td>
<td>Member of an advisory board with AbbVie, Merck, and Paladin Labs for the last 2 years, member of a Speakers bureau with Merck speaking about HPV and VZV vaccinations, and received payment from Merck (including gifts or other consideration or 'in kind' compensation) for HPV and VZV vaccinations.</td>
</tr>
<tr>
<td>Krajden, Mel</td>
<td>Member of an advisory Board or equivalent with Roche and Gilead (money donated to the BCCDC Foundation); received a research contract from Roche, a research grant from Merck, a research contract from Hologic, a research grant from Siemens, and a research contract from Boehringer Ingelheim; and currently participating in or have participated in a clinical trial within the past 2 years funded by CIHR.</td>
</tr>
<tr>
<td>Lee, Christine</td>
<td>Member of a physician advisory board with Rebiotix, Cubist, and Merck, received an honorarium for presentation from Sunovion, received research grants from ViroPharma, Actelion, Cubist, and Merck, and is currently participating in or have participated in a clinical trial within the last 2 years with ViroPharma, Actelion, Cubist, and Merck. Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).</td>
</tr>
<tr>
<td>Levett, Paul</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Lowe, Christopher</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>MacDonald, Noni</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Main, Cheryl</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Thomas, Marrie</td>
<td>Received funding for a research grant from Pfizer.</td>
</tr>
<tr>
<td>Committee Member / Speaker</td>
<td>Disclosure</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>McGeer, Allison</td>
<td>Received research contracts for surveillance of IPD from Pfizer and GSK and is currently participating in or have participated in a clinical trial with the past 2 years related to C. difficile infection with Merck and GSK. Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).</td>
</tr>
<tr>
<td>Minion, Jessica</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Naugler, Christopher</td>
<td>Received payment (including gifts or other consideration or 'in kind' compensation) from Life Labs and Abbott Pharmaceuticals for speakers’ fees and has stock holdings in Mews Labs and Tekmira.</td>
</tr>
<tr>
<td>Oughton, Matthew</td>
<td>Received payment for preparing and giving a presentation to hospital pharmacists (April 2013) from Sunovion (Cubicin), paid for preparing and giving a presentation to provincial INESS board (March-April 2013) from Cubist (Dificid), currently participating in or have participated in a clinical trial within the past 2 years with Merck as the primary investigator for MK3415A - Monoclonal Abs for C. difficile toxins A and B and from Summit as a primary investigator for SMT19969 for Novel oral antibiotic treatment of CDI.</td>
</tr>
<tr>
<td>Patel, Robin</td>
<td>Consultant for St. Jude, Thermo Fisher Scientific, and Curetis, has received payment from a Up-To-Date for royalties and ASM for reimbursement for travel and an editor's stipend, and is currently participating in or has participated in a clinical trial with the past 2 years with Curetis, nanoMR, and Accelerate Diagnostics.</td>
</tr>
<tr>
<td>Patrick, David</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Poutanen, Susan</td>
<td>Member of an Advisory Board or equivalent with Optimer, Cubist, Merck, and Paladin Labs and is member of a speakers bureau with Pathogenica and Merck.</td>
</tr>
<tr>
<td>Quach, Caroline</td>
<td>Received a research grant (paid to institution) from GlaxoSmithKline (2012-2014), AbbVie (2013), and Sage (2013); received an educational grant (paid to institution) from Pfizer (2013), currently participating in or have participated in a clinical trial within the past 2 years with Astellas for Fidaxomicin as a site primary investigator for RCT.</td>
</tr>
<tr>
<td>Richardson, Susan</td>
<td>Currently participating in or has participated in a clinical trial within the past 2 years with Astellas Pharma Global Development Inc. Protocol 9463-CL-2303 Phase 3 study to compare the efficacy and safety of micafungin versus amphotericin B deoxyscholate for the treatment of neonatal candidiasis.</td>
</tr>
<tr>
<td>Rosser, Stuart</td>
<td>Received a speaker honorarium from Pfizer. Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).</td>
</tr>
<tr>
<td>Rotstein, Coleman</td>
<td>Member of an advisory board or equivalent with Merck, member of a speakers bureau with Astellas and Merck, and currently participating in or have participated in a clinical trial within the past 2 years with Astellas, Chimerix, and Merck.</td>
</tr>
<tr>
<td>Shafran, Stephen</td>
<td>Member of an advisory board or equivalent with AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Janssen, Merck, Pfizer, Vertex; received grants or honoraria from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Janssen, Merck, Pfizer, and Vertex; and is currently participating in or have participated in a clinical trial within the past 2 years with AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Janssen, Merck, and Vertex. Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).</td>
</tr>
<tr>
<td>Simmer, Patricia</td>
<td>Information not available at time of publishing.</td>
</tr>
<tr>
<td>Simor, Andrew E.</td>
<td>Member of an advisory board with Cubist, Merck, Optimer, Pendo pharm, Pfizer, and Sunovion; received honoraria from Cubist, Merck, Optimer, Pfizer, and Sunovion for providing consultative services as a member of an Advisory Board or for speaking on their behalf at educational symposia and CME events; and received funding in the form of grants for investigator-initiated research from Pfizer and Sunovion.</td>
</tr>
<tr>
<td>Smyth, Daniel</td>
<td>Received payment for CME events or for attendance at advisory board meetings from AbbVie, Gilead, and Merck and currently participating in or have participated in within the past 2 years with Merck.</td>
</tr>
<tr>
<td>Thirion, Daniel J.G.</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Tremblay, Cécile</td>
<td>Received a research grant from Pfizer and is currently participating in or have participated in a clinical trial within the last 2 years with ANRS - CTN for an ipergay trial.</td>
</tr>
<tr>
<td>Turenne, Christine</td>
<td>Information not available at time of publishing.</td>
</tr>
<tr>
<td>Vinh, Donald</td>
<td>Advisory board member/ consultant with CSL Behring Canada, previous advisory board member (2014) with Pfizer Canada, member of a speakers bureau with CSL Behring Canada and Sunovion, and received an unrestricted educational grant from CSL Behring Canada, and received an investigator-initiated research grant (completed 2014) from Astellas.</td>
</tr>
<tr>
<td>Ward, Brian</td>
<td>Member of ad hoc scientific or clinical advisory committees for almost all vaccine manufacturers from 1995 to present, occasionally give lectures on vaccines and immunomodulatory drugs, received payment from Medicago Inc as a Medical Officer, shared grants with major pharma (investigator initiated as well as clinical trials), received funding for travel and accommodations from Sunovion, and is currently participating in or have participated in a clinical trial within the past 2 years as a primary investigator.</td>
</tr>
<tr>
<td>Webster, Duncan</td>
<td>Participant of an Advisory Board for New Brunswick HCV (February 2014) with AbbVie and is currently participating in or have participated in a clinical trial within the past 2 years with AbbVie for a Topaz trial and Actelion for an Impact trial.</td>
</tr>
<tr>
<td>Wong, Alexander</td>
<td>Received consulting fees and honoraria from Merck, Gilead Sciences, Bristol Myers Squibb, Pfizer, and Janssen; and received funding for regional HIV-related programming from Merck, Gilead Sciences, and Bristol Myers Squibb.</td>
</tr>
<tr>
<td>Wong, Titus</td>
<td>Information not available at time of publishing.</td>
</tr>
</tbody>
</table>
Barrett, Lisa
Dr. Lisa Barrett is Royal College certified in Internal Medicine and Infectious Diseases, in addition to being a fully trained viral immunologist studying chronic viral infection in humans. She is involved in translational Hepatitis C Virus (HCV) direct acting antiviral (DAA) studies at Tony Fauci’s laboratory within the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). These trials assess both clinical and basic pathogenesis questions to comprehensively generate knowledge in both treatment and prevention of HCV research.

Chan, Adrienne
Dr. Adrienne K. Chan is an Infectious Diseases physician and Assistant Professor of Medicine at the University of Toronto. Currently, Dr. Chan serves as Medical Advisor with Dignitas International and is a staff physician at Sunnybrook Health Sciences Centre, Toronto. Dr. Chan’s areas of interest include HIV care and treatment decentralization in low resource settings, integration of TB and HIV services, optimization of Prevention of Mother-To-Child Transmission (PMTCT) initiatives, and innovative task-shifting models in human resources for health. She holds a cross-appointment to the Global Health Division at the Dalla Lana School of Public Health and the Institute for Health Policy, Management and Evaluation at the University of Toronto, where she teaches on Health Systems Management in International Settings.

Over the last nine years, Dr. Chan has worked in southern Africa with clinical experience in Malawi, Lesotho and Zimbabwe. In 2007, Dr. Chan joined Dignitas International, a Canadian non-government organization, as the organization’s HIV Clinic Coordinator in Zomba, Malawi, and later became Medical Coordinator for the Malawi country program. She was seconded to the World Health Organization in 2014/15 as a Clinical Consultant for the Department of Pandemic and Epidemic Diseases, to support the Ebola response in Sierra Leone.

Dr. Chan trained in Internal Medicine and Infectious Diseases at the University of Toronto, where she served as Chief Medical Resident. She earned an MD from the University of Toronto Faculty of Medicine and a Masters in Public Health (Frank Knox Memorial Fellow) at Harvard School of Public Health.

Conly, John
A graduate of the University of Saskatchewan (with distinction), Dr. John Conly is medically trained in internal medicine and infectious diseases and is Board certified in both Canada and the United States. He is the past Chairman of the Department of Medicine, University of Calgary and Alberta Health Services, a past President of the Canadian Infectious Disease Society, a past Chairman of the Board for the Canadian Committee on Antibiotic Resistance, the inaugural Vice Chair for the Canadian Expert Drug Advisory Committee, and founding Co-Chair for the Canadian Hospital Epidemiology Committee which in collaboration with the Public Health Agency of Canada established the current Canadian Nosocomial Infection Surveillance Program. He is currently the Co-Director for the Synder Institute for Chronic Diseases at the University of Calgary, a Board member for the Canadian Foundation for Infectious Diseases, the Editor-in-Chief for the Canadian Journal of Infectious Diseases and Medical Microbiology, an Academic Editor for PLoS One, a member of the World Health Organization (WHO) Technical Consultative Group for the Global Infection Prevention and Control Network, and a Consultant to the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance. He has published over 300 papers and has received multiple career honours in teaching, research, mentorship, innovation and service. He was the recipient of the Ronald Christie Award in 2012 from the Canadian Association of Professors of Medicine which is awarded to a former Chair of a Canadian Department of Medicine who has made outstanding contributions to academic medicine in Canada.

He continues as an active consultant in clinical infectious diseases and his current interests focus on antimicrobial resistance, patient safety, and innovations in healthcare.

Doucette, Karen
Dr. Karen Doucette is an Associate Professor in the Department of Medicine, Division of Infectious Diseases, at the University of Alberta, Education Director for the Transplant Infectious Diseases Fellowship Program and Medical Director of the Hepatitis Support Program.

She completed her undergraduate (BSc) degree and MD at Dalhousie University in Halifax, Nova Scotia. Internal Medicine training at Queen’s University was followed by subspecialty training in Infectious Diseases at the University of Manitoba. While at the University of Manitoba, she undertook additional subspecialty training in viral hepatits. In 2003 she completed a clinical and research fellowship in Transplant Infectious Diseases at the Massachusetts General Hospital. She has been on staff at the University of Alberta since 2004. In 2007 she completed a Master’s in Epidemiology at Harvard School of Public Health.

Dr. Doucette’s research interests include the epidemiology of infections following organ transplantation, herpesvirus infections in transplant recipients, BK virus-associated nephropathy and Hepatitis B and C in both immunocompetent and immunocompromised patients.

Evans, Gerald
Dr. Gerald Evans is the Chair of the Division of Infectious Diseases and a Professor in the Departments of Medicine, Biomedical & Molecular Sciences, and Pathology & Molecular Medicine at Queen’s University and an Infectious Diseases physician at Kingston General Hospital in Kingston, Ontario.

Dr. Evans is Past President of AMMI Canada and Past Chair of the Committee to Evaluate Drugs of the Ontario Ministry of Health and Long-Term Care, the Ministry’s expert advisory committee on optimal drug utilization. He is currently a co-investigator with the Ontario Drug Policy Research Network, the Chair of the AMMI Canada Guidelines Committee, and the provincial lead for Antibiotic Stewardship with Public Health Ontario.

Falzarano, Darryl
Dr. Darryl Falzarano is a Research Scientist at the Vaccine and Infectious Disease Organization – International Vaccine Center (VIDO-InterVac) at the University of Saskatchewan. He received his Ph.D. from the Department of Medical Microbiology at the University of Manitoba in 2010 for determining the functional importance of post-translation modifications of Ebola virus glycoproteins. He then went on to complete post-doctoral studies at Rocky Mountain Laboratories, part of the National Institute of Allergy and Infectious Disease, in Hamilton, Montana. There, he investigated antiviral and immunomodulation strategies for Ebola and Middle East respiratory syndrome coronavirus (MERS-CoV). This included the development of a new animal model and the first potential treatment for MERS-CoV.

Dr. Falzarano has 10 years of experience working in high containment (CL-3 and CL-4) laboratories with Ebola, Marburg, MERS-CoV and Lassa. While at the National Institutes of Health (NIH) he received the
Celebrating 10 years of collaboration

Célébrons 10 années de collaboration

Dr. A. Mark Joffe pursued undergraduate studies in Immunology. He is a Professor in the Department of Medicine at the University of Alberta. His specialty practice in Infectious Diseases is based at the Royal Alexandra Hospital. He is also a Staff Physician at the Edmonton Sexually Transmitted Diseases Centre and the Edmonton Institution for Women, a federal correctional facility. He is the Senior Medical Director for Infection Prevention and Control for Alberta Health Services. He has served as President of the Royal Alexandra Medical Staff Society and 2 terms as President of the Capital Region Medical Staff Association. He recently completed a 2-year term as President of the Association of Medical Microbiology and Infectious Diseases of Canada and is now Past-President. His major interests are in the prevention of infectious diseases in both patients and health care workers in acute care hospitals.

Dr. Todd Hatchette is currently the Chief of Service for the Division of Microbiology, Queen Elizabeth II (QEII) Health Science Center and the Director of the Virology and Immunology. He is a Professor in the Department of Pathology with cross appointments in the Departments of Immunology and Microbiology and Medicine where he is a consultant Infectious Diseases. As the province’s only medical virologist, Dr. Hatchette has expertise in the clinical and laboratory diagnosis of viral infections and has given continuing medical education (CME) lectures to various health care professionals. He serves as an advisor on a number of local and provincial committees.

Dr. Noni MacDonald is a Professor of Paediatrics and Molecular Medicine at McMaster University, Medical Director of Infection Prevention and Control at St. Joseph’s Healthcare, Discipline Director of Microbiology for the Hamilton Regional Laboratory Medicine Program. Dr. Lee received her MD from the University of Toronto where she also completed her Internal Medicine, Infectious Diseases and Medical Microbiology residency.

MacDonald, Noni

Dr. Noni MacDonald is a Professor of Paediatrics (Infectious Diseases) at Dalhousie University and the IWK Health Centre in Halifax and a former dean of Medicine at Dalhousie University. She received her BSc in Microbiology and Immunology from Queen’s University, her MD and MSc from the University of Ottawa and completed her RCPs paediatic fellowship training also at the University of Ottawa and CHEO with her infectious diseases fellowship training at McGill and then the University of Rochester. She was the first paediatrician to be RCPs certified in Infectious diseases. She is also a fellow of Green College Oxford and of the Canadian Academy of Health Sciences.

Her current three major areas of interest are 1) Vaccines, especially vaccine hesitancy, vaccine safety, vaccine pain mitigation at immunization and Adverse Events Following Immunization (AEFI) surveillance in pregnant women through her work with the World Health Organization as well as vaccine pain and hesitancy research and policy work in Canada; 2) MicroResearch, building capacity in community focused research in developing countries (www.microresearch.ca), and 3) application of Health Information Systems in developing countries to improve health outcomes. She has published over 300 papers; is the founding Editor-in-Chief of Paediatrics and Child Health, and a former Editor-in-Chief of CMAJ (Canadian Medical Association Journal). Dr. MacDonald has long been recognized in Canada and internationally, as an advocate for child and youth health and as a leader in paediatric infectious disease.
faculty at Dalhousie where, over 22 years, he built a distinguished career as a teacher, researcher and clinician. While a professor in the departments of medicine and microbiology at Dalhousie, Dr. Marrie established the Division of Infectious Diseases.

In 1999, Dr. Marrie was recruited to the University of Alberta to head the Department of Medicine. In 2004, he was appointed Dean of the University of Alberta’s Faculty of Medicine and Dentistry. Under his leadership, the Faculty engaged in a major capital expansion with the construction of two health research buildings. He also developed an alternative funding plan that offered a new method to support faculty, enabling greater academic activity and more innovative patient care.

Well known across the country as an infectious diseases specialist, Dr. Marrie has maintained an active research program focusing on community-acquired pneumonia (CAP). Through his research, numerous publications and frequent lectures, he has contributed significantly to knowledge about CAP, particularly in the areas of outcomes and health services.

Dr. Marrie’s leadership on numerous national committees and boards includes terms as associate editor of “Physical Signs” for the American Journal of Medicine, president of the Canadian Association of Professors of Medicine, and president of the Canadian Infectious Disease Society.

His contributions have been recognized with numerous awards, including the Excellence in Leadership Award (University of Alberta), a Master Clinician Lecturer Award (Department of Medicine, Dalhousie University), a Lifetime Achievement Award (Association of Medical Microbiology and Infectious Diseases of Canada), and a honorary doctorate (University of Mediterranean, Marseille, France). The University of Alberta has named a lectureship in Global Health and Infectious Diseases and two awards (in Dental Hygiene and in Dentistry) in Dr. Marrie’s honour.

During the first four years of his leadership at Dalhousie Medical School, the undergraduate curriculum has been completely renewed, and research laboratories have been built at Dalhousie Medicine New Brunswick. Three basic science researchers have been recruited to support these labs, along with a research chair in occupational medicine.

**McGee, Allison**

Dr. Allison McGee is a Microbiologist and Infectious Disease Consultant, Director of Infection Control, and Director of the Infectious Diseases Epidemiology Research program at Mount Sinai Hospital; and Professor of Laboratory Medicine and Pathobiology and Public Health Sciences at the University of Toronto.

Dr. McGee trained in internal medicine and infectious diseases at the University of Toronto, then completed a fellowship in hospital epidemiology at Yale New Haven Hospital in 1989/90 before returning to Mount Sinai Hospital. Her research interests are in the prevention of infection in health care institutions and control of antimicrobial resistance.

**Naugler, Christopher**

Dr. Christopher Naugler is a family physician with extensive clinical experience as well as a general pathologist and clinician-scientist at the University of Calgary Cumming School of Medicine. He is the author of over 90 peer-reviewed publications and 4 books. His research interests are in clinical epidemiology, laboratory utilization, pathology informatics image analysis and data mining.

Dr. Naugler is an Associate Professor in the Department of Pathology and Family Medicine at the University of Calgary, Division Head of General Pathology for Alberta Health Services Calgary Zone, Section Head of Pathology Informatics for Calgary Laboratory Services, Program Director of the University of Calgary General Pathology Residency Training program and medical director of the Alberta Health Services, Provincial Laboratory Utilization Office. Dr. Naugler was the 2014 winner of the University of Calgary, Faculty of Medicine Watanabe Distinguished Achievement Award for Overall Excellence.

**Patel, Robin**

Dr. Robin Patel graduated from Princeton University with a BA in Chemistry in 1985 and from McGill University in Montreal, Canada with an M.D.(C.M.) in 1989. She then moved to Rochester, Minnesota, where she completed residencies in Internal Medicine and Microbiology and a fellowship in Infectious Diseases at the College of Medicine, Mayo Clinic. In 1996, upon completion of post-graduate training, she joined the staff of the Mayo Clinic. She is currently Professor of Medicine, a Professor of Microbiology, Director of the Clinical Bacteriology Laboratory and the Infectious Diseases Research Laboratory, and Chair of the Division of Clinical Microbiology, at the Mayo Clinic.

Dr. Patel is board certified in Infectious Diseases (American Board of Internal Medicine), Medical Microbiology/Public Health Microbiology (American Board of Medical Microbiology), Clinical Pathology/Medical Microbiology (American Board of Pathology), and Internal Medicine, Medical Microbiology and Infectious Diseases (Collège des Médecins du Québec and Royal College of Physicians and Surgeons of Canada).

Dr. Patel’s research focuses on clinical bacteriology diagnostic testing, antimicrobial resistance, and microbial biofilms. She has published over 250 peer-reviewed manuscripts and has delivered numerous national and international presentations. She is a Fellow of American Academy of Microbiology, a past member of the IDWeek Program Planning Committee, the Chair of the United States Medical Licensing Examination Microbiology and Immunology Test Material Development Committee and the Vice Chair of the ICAAC Program Planning Committee. She is an Associate Editor for the Journal of Clinical Microbiology, and the Course Director for the Mayo Medical School Microbiology course.

**Poutanen, Susan**

Dr. Susan Poutanen received her Medical Degree from the University of Toronto in 1996 and completed Internal Medicine and Medical Microbiology Residencies at the University of Toronto and an Infectious Diseases Fellowship at Stanford University, California. She received her Masters of Public Health with a focus on Epidemiology from the University of California, Berkeley in 2002.

Dr. Poutanen is a Medical Microbiologist and Infectious Diseases Physician at Mount Sinai Hospital & University Health Network in Toronto, Canada and an associate professor in the Department of Laboratory Medicine and Pathobiology and Department of Medicine at the University of Toronto. Her broad research interests include the epidemiology and detection of antimicrobial resistance; the diagnosis of, preparedness for, and treatments of emerging and re-emerging infectious diseases; and the optimization of microbiology laboratory practices to support antimicrobial stewardship and patient care.

**Rosser, Stuart**

Dr. Stuart Rosser obtained his MD from the University of Alberta in 1988. His career development from that point followed a non-linear path, including sojourns in Toronto, northern Ontario, New Zealand, Rochester, Minnesota, Jacksonville, Florida, Cambridge, Massachusetts, and Winnipeg, Ontario. In 2006, he returned to the University of Alberta. In his work as an infectious disease consultant at the Royal Alexandra hospital in Edmonton, he developed close working relationships with the regional arthroplasty and home parenteral therapy programs, which stimulated and perpetuated his interest in device-associated infections.
Rotstein, Coleman

Dr. Coleman Rotstein is Professor of Medicine in the Division of Infectious Diseases at the University of Toronto and Attending Physician at the University Health Network in Toronto, Ontario. He received a Bachelor’s of Science at the University of Toronto and earned his medical degree from the University of Calgary in 1976. Dr. Rotstein completed his specialty training in Internal Medicine at the University of Toronto and pursued further subspecialty training in Infectious Diseases & Immunology at the Medical University of South Carolina in Charleston, South Carolina from 1980 to 1983 (ABIM (1980), FRCP (Internal Medicine 1981), Infectious Diseases ABIM (1982)).

Dr. Rotstein is currently the Director of Oncologic Infectious Diseases at Princess Margaret Hospital and Co-director of Transplant Infectious Diseases at the University Health Network. He is also the former Director of the Division of Infectious Diseases at McMaster University, past Chair and current Secretary of the Infectious Diseases Section of the Ontario Medical Association, former Co-chair of the Emerging Infectious Diseases Network, former Past-President of the Association of Medical Microbiology and Infectious Disease Canada, former President of the Canadian Infectious Disease Society, and former Chair of the Clinical Trials Committee of the Canadian Infectious Disease Society. In addition, he has been elected a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is a reviewer for several international journals and was formerly the Associate Editor, Review Section, for the Canadian Journal of Infectious Diseases and Medical Microbiology.

Dr. Rotstein has published over 150 peer-reviewed papers. His research interests have focused mainly on antibacterial agents, infections in cancer patients and other immunocompromised hosts as well as fungal infections caused by Candida organisms. He maintains active research interests in clinical trials involving antifungal and antiviral agents in immunocompromised hosts.

Shafran, Stephen

Dr. Stephen D. Shafran received his MD from the University of Toronto and trained in Internal Medicine at the University of Toronto and in Infectious Diseases at the University of British Columbia. After an initial academic appointment at the University of Saskatchewan, he moved to the University of Alberta in 1989. He has held the positions of Director of the Infectious Diseases Training Program, Director of Undergraduate Education for the Department of Medicine and Director of the Division of Infectious Diseases. He has served the Canadian Infectious Disease Society (precursor to AMMI Canada) in several capacities, including as President. He has received teaching awards from both the University of Saskatchewan and the University of Alberta. He received an award from the American Society for Microbiology for the best abstract in the subject of antiviral therapy. His research focuses on clinical trials of antiviral agents. He has over 100 publications and over 100 abstracts. His outpatient practice is focused primarily on HIV, HCV, and HBV infections. He also provides hepatitis and HIV care to inmates in two Federal prisons in northern Alberta.

Simor, Andrew E.

Dr. Andrew Simor graduated with a medical degree from the University of Toronto in 1976 and completed Royal College fellowship training in internal medicine, infectious diseases, and medical microbiology. He has worked at Sunnybrook Health Sciences Centre since 1993. Dr. Simor is recognized nationally and internationally as a leader in the field of hospital epidemiology. He has received research funding from peer-reviewed and industry-based granting agencies. He has published a large number of papers in scientific journals, he is on the Editorial Board of the journal, Infection Control and Hospital Epidemiology, and is an Associate Editor for the Canadian Journal of Infectious Diseases and Medical Microbiology. His primary research interests include: antimicrobial resistance, hospital-acquired infections, and the application of molecular technologies to the diagnosis and management of infectious diseases.

Dr. Simor has received several teaching award from the university, and in 2005 was selected to receive the Distinguished Service Award from the university’s Department of Laboratory Medicine & Pathobiology. He has also received a Canadian Hospital Infection Control Association Award of Merit for service in the advancement of infection prevention and control.

Smyth, Daniel

Dr. Daniel Smyth graduated from Dalhousie Medical School in 2006 and completed internal medicine training at the Queen Elizabeth II (QEI) Health Sciences Centre in Halifax. He completed infectious disease training at the University of Calgary in 2011 and now holds a staff position at the Moncton Hospital, through which he holds an academic affiliation with Dalhousie University. His clinical and research interests include chronic viral infections, antimicrobial stewardship, and travel/tropical medicine. Dr. Smyth has lead New Brunswick and Prince Edward Island clinicians in the creation of clinical programming for patients with chronic HCV infection, which has been instrumental to the launch of a comprehensive HCV treatment strategy including public access to interferon-free curative regimens on PEI. Dr. Smyth is the director of research for the Research, Education and Clinical Care of At-Risk Populations (RECAP) program in New Brunswick and lead investigator on several comprehensive treatment and outcome registries currently enrolling in Atlantic Canada.

Thirion, Daniel J.G.

Dr. Daniel J.G. Thirion is currently Clinical Full Professor of pharmacy at the Université de Montréal where his teaching responsibilities are focused on infectious diseases pharmacotherapy. As pharmacist, he is Co-Chair of the antimicrobial stewardship program at the McGill University Health Center.

He earned his Doctor of Pharmacy degree from the College of Pharmacy at Wayne State University, Detroit, Michigan (1999), his Bachelor of Pharmacy (1996) and Masters of Science (1997) from Université de Montréal in Montréal, Québec. He completed post-doctoral training in infectious diseases at University of California, San Francisco. He is recognized as Fellow of the Canadian Society of Hospital Pharmacists. Prior to coming to Montreal in 2001, he was adjunct faculty at the School of Pharmacy, Auburn University in Alabama and a clinical pharmacist at Columbus Regional Healthcare System in Georgia.

His research focuses on the impact of antimicrobial use on emerging diseases and development of resistance, and appropriate use of antimicrobials in clinical practice. He has published over 100 articles and book chapters, served as invited speaker for over 300 conferences, and trained numerous pharmacy graduate students. He is also editor, publisher, and author of the “Snippets for Snappy Antimicrobial Therapy”, an award winning reference for infectious disease (ID) pharmacotherapy.

His clinical practice is focused on providing pharmaceutical care in infectious diseases for tertiary care hospitals. His teaching responsibilities include ID pharmacotherapy for the undergraduate and graduate programs and development of the PharmD. program. He has also assumed the role of President of the Association of Faculties of Pharmacy in Canada (AFPC) over the past year. As a recognized expert, he devotes time and effort in his field of interest for committees, juries, and advisory boards up to the international level.

Celebrating 10 years of collaboration

Célébrons 10 années de collaboration
Vinh, Donald
Dr. Donald Vinh obtained his medical degree in 2001 from McGill University. He then completed a residency in Internal medicine at McGill University (Jewish General Hospital), followed by a combined fellowship in Clinical Infectious Diseases at the University of Manitoba and in Medical Microbiology at McGill. He subsequently completed a post-doctoral translational research fellowship at the National Institutes of Health (NIH) to understand inborn errors of immunity that render humans susceptible to infections, particularly fungal diseases. This research, in the laboratory of Dr. Steve Holland, was supported by a Canadian Institutes of Health Research (CIHR) post-doctoral fellowship award as well as a NIH Visiting Fellow award. This work focused on understanding chronic granulomatous disease, autosomal-dominant hyper-IgE (Job’s) syndrome, and defects in the interleukin (IL)-12/interferon (IFN)-gamma axis. It culminated in the discovery of a new genetic immunodeficiency, MonoMac syndrome, due to mutations in GATA2. His work earned him the Canadian Foundation for Infectious Diseases Excellence in Infectious Disease Research Award in 2010 and the 2013-2014 National Institute of Allergy and Infectious Diseases (NIAID) Merit Group Award as a member of the GATA2 Discovery Group (for outstanding clinical and basic research leading to the discovery and characterization of GATA2 Deficiency).

Dr. Vinh is a member of the Microbiology Organizational Committee, Microbiology Protocol Committee, and the Pharmacy & Therapeutic Antimicrobial sub-committee at the McGill University Health Centre. He is on the Guidelines Committee for the Association of Medical Microbiologists and Infectious Disease (AMMI Canada), for which he has co-authored the guidelines on candidiasis. He is also a member of the Clinical Immunology Society Communications Committee and an active member of the International Immunocompromised Host Society (IHS), Clinical Immunology Society (CIS), European Society for Immunodeficiencies (ESID) and the American Society of Microbiology (ASM), for which he has been an invited speaker on several occasions.

Dr. Vinh is an Assistant Professor and Clinician-Scientist in the Division of Infectious Diseases and the Division of Allergy & Clinical Immunology, in the Department of Medicine at the MUHC. He is also Assistant Professor in the Department of Medical Microbiology and Affiliate in the Department of Human Genetics. He is the Director of the Infectious Disease Susceptibility Program at the McGill University Health Centre (MUHC), a translational research program on Genetic Immune Deficiencies.

Ward, Brian
Dr. Brian Ward received medical training at McGill University, University of London and Johns Hopkins Hospital (Tropical Medicine, Infectious Diseases, Microbiology). His research training began as a Rhodes scholar at Oxford University and continued at Johns Hopkins. He joined the Faculty of Medicine at McGill in 1991. He is currently a Professor of Medicine and Deputy Director of the Research Institute of the McGill University Health Centre. He is also the Associate Director of the JD MacLean Centre for Tropical Diseases, Director of the McGill Vaccine Study Centre and Director of the National Reference Laboratory for Parasitology. Since late 2010, he has served as the Medical Officer for Medicago Inc, a company in Québec City using plants to make vaccines. His research interests include micronutrient-virus interactions, nanoparticle vaccines, parasite diagnostics and HIV transmission. He has published >225 peer-reviewed manuscripts/chapters and was recently elected to the Canadian Academy of Health Sciences. His international research has been carried out with colleagues in Peru, Zimbabwe, Sudan, Haiti, Thailand and Venezuela among other countries.
Exhibitor Directory

Abbott Laboratories, Limited
BOOTH # 44
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. We are displaying products from our Molecular and Diagnostic Divisions.

Brian Fellows
National Accounts Manager
7115 Millcreek Drive
Mississauga, Ontario L7M 4J5
Email: brian.fellows@abbott.com

AbbVie Corporation
BOOTH # 40
AbbVie is a global, research-based biopharmaceutical company working to address some of the world’s most complex and serious diseases, such as hepatitis C.

Annie Beauparlant
CHE Project Manager - HCV
8401 Trans-Canada Highway
Saint-Laurent, Quebec H4S 1Z1
Phone: (514)703-0037
Email: annie.beauparlant@abbvie.com
Website: www.abbvie.ca

Affinity Diagnostics Corp.
BOOTH # 31
Affinity Diagnostics Corp. provides a wide variety of ELISA-based infectious disease assays and laboratory automation, allowing us to provide custom solutions to Canadian laboratories of all sizes. Visit us at www.affinitydiagnostics.ca, or call us at 877-370-6300.

Daniel Libertucci
Managing Director
194 Wildcat Road
Toronto, Ontario M3J 2N5
Phone: (416)674-7280
Fax: (416)650-5990
Email: sales@affinitydiagnostics.ca
Website: www.affinitydiagnostics.ca

Alere Canada
BOOTH # 45
Alere Canada a foremost leader in laboratory diagnostics that delivers reliable and actionable information through rapid diagnostic tests resulting in better clinical outcomes. Alere has well respected brands specializing in the areas of cardiovascular and infectious disease. Alere has recently launched Alere i, the first CLIA waived rapid molecular diagnostic assay for influenza A & B.

Kim Orr
Marketing Co-ordinator
1 - 57 Iber Road
Ottawa, Ontario K2S 1E7
Phone: (613)271-1144
Fax: (613)271-1148
Email: kim.orr@alere.com
Website: www.alere.ca

Association of Medical Microbiology and Infectious Disease Canada
BOOTH # 14
The Association of Medical Microbiology and Infectious Disease (AMMI) Canada is the national association that represents physicians, clinical microbiologists and researchers specializing in the fields of medical microbiology and infectious diseases. Through promotion of the diagnosis, prevention and treatment of human infectious diseases, and by our involvement in education, research, clinical practice and advocacy, AMMI Canada aims to serve and educate the public and also to enhance the career opportunities of its members through professional development and advocacy initiatives.

Riccarda Galioto
Chief Operations and Meetings Officer
192 Bank Street
Ottawa, Ontario K2P 1W8
Phone: (613)260-3233, ext. 102
Fax: (613)260-3235
Email: manager@ammi.ca
Website: www.ammi.ca

BD Diagnostics
BOOTH # 41
BD is a global leader serving the needs of clinicians and healthcare professionals across the healthcare continuum. BD Diagnostic Systems deliver innovative solutions to the laboratory and broader healthcare setting that improve patient outcomes by reducing variability, increasing accuracy and minimizing time to actionable results.

Chris Mitchell
Associate Product Manager
100 - 2100 Derry Road West
Mississauga, Ontario L5N 0B3
Phone: (905)288-6000
Fax: (905)288-6006
Email: chris_mitchell@bd.com
Website: www.bd.com

Bio-Rad Laboratories Canada
BOOTH # 48
Bio-Rad Laboratories is one of the biggest leading diagnostics companies worldwide. It is recognized for its leadership position in quality control, diabetes monitoring, autoimmune diseases and microbiology.

Louis Beaudoin
National Sales Manager
2403 Guénette
Montréal, Québec H4R 2E9
Phone: (514)334-4372
Fax: (514)334-4415
Email: louis.beaudoin@bio-rad.com
Website: www.bio-rad.com

Bristol-Myers Squibb Canada
BOOTH # 21
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bmscanada.ca.

Richard Arlen
Launch Lead HCV
2344 Alfred-Nobel Boulevard
St-Laurent, Québec H4S 0A4
Phone: (514)333-4893
Email: Richard.Arlen@bms.com
Website: www.bmscanada.ca

Bio Nuclear Diagnostics Inc.
BOOTH # 49
BND is a leading supplier of infection control, diagnostic, medical disposable and laboratory products. Focus Diagnostics molecular detection platform and EIAs. Our own medical disposable and laboratory product brand is “Technologist Choice”.

Ivana Mastilo
Technical Sales Representative
1791 Albion Road
Toronto, Ontario M9W 5S7
Phone: (416)301-9539
Fax: (416)674-7280
Email: ivana.mastilo@bndinc.com
Website: www.bndinc.com

BIO-RAD LABORATORIES CANADA
BOOTH # 21
Bio-Rad Laboratories is one of the biggest leading diagnostics companies worldwide. It is recognized for its leadership position in quality control, diabetes monitoring, autoimmune diseases and microbiology.

Louis Beaudoin
National Sales Manager
2403 Guénette
Montréal, Québec H4R 2E9
Phone: (514)334-4372
Fax: (514)334-4415
Email: louis.beaudoin@bio-rad.com
Website: www.bio-rad.com

Bristol-Myers Squibb Canada
BOOTH # 21
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bmscanada.ca.

Richard Arlen
Launch Lead HCV
2344 Alfred-Nobel Boulevard
St-Laurent, Québec H4S 0A4
Phone: (514)333-4893
Email: Richard.Arlen@bms.com
Website: www.bmscanada.ca

Bio Nuclear Diagnostics Inc.
BOOTH # 49
BND is a leading supplier of infection control, diagnostic, medical disposable and laboratory products. Focus Diagnostics molecular detection platform and EIAs. Our own medical disposable and laboratory product brand is “Technologist Choice”.

Ivana Mastilo
Technical Sales Representative
1791 Albion Road
Toronto, Ontario M9W 5S7
Phone: (416)301-9539
Fax: (416)674-7280
Email: ivana.mastilo@bndinc.com
Website: www.bndinc.com

BIO-RAD LABORATORIES CANADA
BOOTH # 21
Bio-Rad Laboratories is one of the biggest leading diagnostics companies worldwide. It is recognized for its leadership position in quality control, diabetes monitoring, autoimmune diseases and microbiology.

Louis Beaudoin
National Sales Manager
2403 Guénette
Montréal, Québec H4R 2E9
Phone: (514)334-4372
Fax: (514)334-4415
Email: louis.beaudoin@bio-rad.com
Website: www.bio-rad.com

Bristol-Myers Squibb Canada
BOOTH # 21
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bmscanada.ca.

Richard Arlen
Launch Lead HCV
2344 Alfred-Nobel Boulevard
St-Laurent, Québec H4S 0A4
Phone: (514)333-4893
Email: Richard.Arlen@bms.com
Website: www.bmscanada.ca

Bio Nuclear Diagnostics Inc.
BOOTH # 49
BND is a leading supplier of infection control, diagnostic, medical disposable and laboratory products. Focus Diagnostics molecular detection platform and EIAs. Our own medical disposable and laboratory product brand is “Technologist Choice”.

Ivana Mastilo
Technical Sales Representative
1791 Albion Road
Toronto, Ontario M9W 5S7
Phone: (416)301-9539
Fax: (416)674-7280
Email: ivana.mastilo@bndinc.com
Website: www.bndinc.com
Canadian Foundation for Infectious Diseases

BOOTH # 13

CFID is a charitable organization committed to improving the health of Canadians through the support of research and dissemination of knowledge pertaining to infectious diseases. CFID’s vision is to achieve effective research outcomes, strong and extensive stakeholder connections, successful advocacy and a positive impact on public policy.

Dr. Susan Richardson
President, CFID

c/o The Hospital for Sick Children
Microbiology, Room 3654 Atrium
55 University Avenue
Toronto, Ontario M5G 1X8

Phone: (416)813-5992
Email: cfid@researchid.com
Website: www.researchid.com

CEDARLANE

BOOTH # 29

CEDARLANE® provides ATCC bacterial/viral controls, Millipore’s DFA kits, SSI’s Strept. Pneumo kit, Altona Diagnostics’ PCR kits, Biomed Diagnostics’ media system and AdvanDX’s rapid pathogen detection platform.

Eddie Johnson
General Manager

4410 Paletta Court
Burlington, Ontario L7L 5R2

Phone: (289)288-0001
Toll-free: 1(800)268-5058
Fax: (289)288-0020
Email: eddie.johnson@cedarlanelabs.com
Website: www.cedarlanelabs.com

CIHR – Institute of Infection and Immunity (III)

BOOTH # 50

CIHR is the federal agency responsible for funding health research in Canada, and III supports research and builds capacity in the areas of infectious diseases and the immune system.

Jennifer Raven
Assistant Director

2705 Laurier Boulevard, TR62
Québec City, Québec G1V 4G2

Phone: (418)577-4688
Fax: (418)577-4689
Email: jennifer.raven@cihr-irsc.gc.ca
Website: www.cihr-irsc.gc.ca/e/13533.html

Copan Diagnostics

BOOTH # 47

With a reputation for innovation in preanalytics, Copan is the leading manufacturer of collection and transport systems. Copan’s collaborative approach has resulted in Flocked Swabs, ESwab, Universal Transport Medium and laboratory automation, WASP® and WASPLab.

Jane Lukashevsky
Business Development Manager, Canada

26055 Jefferson Avenue
Murrieta, California 92562 USA

Phone: 1(800)216-4016
Fax: 1(800)600-1832
Email: info@copanusa.net
Website: www.copanusa.com

Diasorin Canada Inc.

BOOTH # 38

Diasorin, the Diagnostic Specialist, provides specialized reagents and automated diagnostic instrumentation for laboratories. Diasorin offers immunodiagnostic assays for infectious diseases, autoimmune, bone and endocrine diseases, as well as automated nucleic acid purification from clinical samples.

Jeff Kormos
Commercial Director & Country Manager

Units 3 & 4, 2nd Floor,
205 Export Boulevard
Mississauga, Ontario L5S 1Y4

Phone: (905)677-1600
Toll-free: 1(855)677-0600
Fax: (905)677-1630
Email: jeff.kormos@diasorin.com
Website: www.diasorin.com

Gilead Sciences

BOOTH # 11

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases. Gilead’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Geoffrey Christie
HCV Marketing - OLP

600 - 6711 Mississauga Road
Mississauga, Ontario L5N 2W3

Phone: (647)225-2642
Fax: (905)363-8019
Email: geoffrey.christie@gilead.com
Website: www.gilead.com

Hologic, Inc.

BOOTH # 28

Hologic is committed to improving lives through the development of premium diagnostics utilizing the latest technology for molecular testing, cervical health screening and cytology preparation. We continue to expand our offering with superior automation platforms and a growing menu of molecular tests for infectious diseases. Our clinical diagnostic solutions are designed to benefit laboratories, clinicians and the patients they serve.

Bihn Ly
Account Executive

10210 Genetic Center Drive
San Diego, California 92121 USA

Phone: 1(800)442-9892, ext. 74195
Email: Bihn.Ly@hologic.com
Website: www.hologic.com
IDWeek 2015
BOOTH # 10
IDWeek is the premier international meeting in infectious diseases – October 7-11 in San Diego. Now accepting abstracts, travel grants available, visit www.idweek.org to apply.

John Buckley
DIRECTOR, MEETING SERVICES
300 - 1300 Wilson Boulevard
Arlington, Virginia 22209 USA
Phone: (703)299-0200
Fax: 1(866)579-0939
Email: jbuckley@idsociety.org
Website: www.idweek.org

INNOVATEK MEDICAL
BOOTH # 18
A Canadian company selling rapid diagnostic kits in the areas of drugs of abuse, women’s health and infectious diseases. Our primary focus is on innovation for clinical laboratory technology.

Marcus Titian Parsad
NATIONAL SALES MANAGER
3 - 1600 Derwent Way
Delta, British Columbia V3M 6M5
Phone: (604)522-8303
Fax: (604)522-8318
Email: marcus@innovatekmed.com
Website: www.innovatekmed.com

INTER MEDICO
BOOTH # 58
Inter Medico provides automated technology solutions for rapid PCR molecular testing such as MRSA, VRE, C. difficile and Flu, plus other general microbiology reagents.

Carl Garnett
MARKETING MANAGER
50 Valleywood Drive
Markham, Ontario L3R 6E9
Phone: 1(800)387-9643
Fax: (905)470-2381
Email: cgarnett@inter-medico.com
Website: www.inter-medico.com

KORONA MOLECULAR CORP.
BOOTH # 56
Clinical molecular diagnostic reagents and platforms.

Jamie Yantzzi
Phone: (416)995-9849
Email: jyanzti@koronadx.com

LABWARE INC.
BOOTH # 51
LabWare provides proven software solutions for public health, biobanking clinical research, clinical trials and reference laboratories.

David Trottier
BUSINESS DEVELOPMENT MANAGER
102 - 3 Mill Road
Wilmington, Delaware 19806 USA
Phone: (302)830-9153 (302)658-8444
Fax: (302)658-7894
Email: trottier@labware.com
Website: www.labware.com

LUMED
BOOTH # 60
Our mission is to optimize clinical practice, improve the quality of patient care and reduce costs. We provide cutting edge software solutions like APSS, the first Canadian antimicrobials prescription surveillance system with demonstrated impacts on hospital spending.

Vincent Nault, PhD (c)
CEO
168, rue Boisé
Canton Hatley, Québec J0B 2C0
Phone: (819)574-2471
Fax: (819)829-3286
Email: info@lumed.ca
Website: www.lumed.ca

LUMINEX CORPORATION
BOOTH # 62
Luminex pioneers comprehensive molecular diagnostics systems and assays, offering multiplex solutions for infectious diseases, newborn genetics and pharmacogenomics to all clinical diagnostics laboratories.

Maryam Calderone
DIAGNOSTICS BUSINESS MANAGER - CANADA
900 - 439 University Avenue
Toronto, Ontario MSG 1Y8
Phone: (416)617-3082
Email: mcalderone@luminexcorp.com
Website: www.luminexcorp.com

MERCK CANADA INC.
BOOTH # 1
Today’s Merck is a global healthcare leader working to help the world be well. Through our medicines, vaccines, therapies and products, we work with customers to deliver innovative health solutions. Please visit www.merck.ca.

Debra Manning
EXHIBITS & CONVENTIONS
16750 Trans-Canada Highway
Kirkland, Québec H9H 4M7
Phone: (514)428-3477
Email: debra.manning@merck.com
Website: www.merck.ca

NOSOTEC
BOOTH # 24
Nosotech provides the most complete and efficient software solutions for antimicrobial stewardship and infection control combining user-friendly solutions, top clinical expertise and best-in-class customer support.

Laurent Bellavance
GENERAL MANAGER
215 - 133 Julien Réhel
Rimouski, Québec G5L 9B1
Phone: (418)723-0862
Email: laurent.bellavance@nosotech.com
Website: www.nosotech.com

PAALINLABS
BOOTH # 65
Paladin Labs, headquartered in Montreal, Quebec, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

Josée Moreton, MBA
PRODUCT MANAGER
600 - 100 Alexis Nihon Boulevard
St. Laurent, Quebec H4M 2P2
Phone: (514)215-8486
Fax: (514)344-4675
Email: jmoreton@paladinlabs.com
Website: www.paladinlabs.com

NovaTec Immundiagnostica GmbH
BOOTH # 23
NovaTec Immundiagnostica GmbH is a manufacturer and research and development company of diagnostic test kits. We are expert in infectious diseases, hormones, tumour markers, autoimmune diseases and allergies. Our products include ELISA, qPCR and Blots.

Rodrigo Berlie
DIRECTOR OF MARKETING AND NEW BUSINESS DEVELOPMENT
Waldstrasse 23A6,
Dietzenbach 63128 GERMANY
Phone: +49 6074 4876 0
Fax: +49 6074 4876 29
Email: marketing@novatec-id.com
Website: www.novatec-id.com

Celebrating 10 years of collaboration
Célébrons 10 années de collaboration
Celebrating 10 years of collaboration

**Pfizer Canada Inc.**  
**BOOTH # 25**  
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world’s leading biopharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines and vaccines for humans. At Pfizer, we’re working together for a healthier world. For more information, visit www.pfizer.ca.

**Nathalie Labonté**  
**CHE MANAGER**  
17300 Trans-Canada Highway  
Kirkland, Québec H9J 2M5  
Email: nathalie.labonte@pfizer.com  
Website: www.pfizer.ca

**Phoenix Airmid Biomedical Corp.**  
**BOOTH # 32**  
Phoenix Airmid Biomedical provides Canadian laboratories with high performance results and flexibility across multiple platforms through our comprehensive menu of molecular diagnostic kits and controls for infectious diseases.  
1166 South Service Road West  
Oakville, Ontario L6J 7L6  
Email: info@phoenixairmid.com  
Website: www.phoenixairmid.com

**Populus Global Solutions Inc.**  
**BOOTH # 63**  
Populus Plus is a cloud-based EMR that helps physicians achieve more. Seamlessly transition from data collection, to analysis to collaboration. Anywhere, anytime, any device.  
590 Brunswick Street  
Fredericton, New Brunswick E3B 1H5  
Email: nigel.orfei@populusgs.com  
Website: www.populusgs.com

**Promega Corporation**  
**BOOTH # 17**  
Promega has over 35 years of expertise delivering instruments and reagents to life science and clinical laboratories. Our portfolio includes IVD and RUO products.  
**Ron Kolojek**  
**CLINICAL ACCOUNT MANAGER**  
2800 Woods Hollow Road  
Madison, Wisconsin 53711 USA  
Phone: (608)274-4330  
Fax: (608)277-2601  
Email: ron.kolojek@promega.com  
Website: www.promega.com

**Pulsus Group Inc.**  
**BOOTH # 15**  
Pulsus Group is a Canadian publishing company specializing in high-quality peer-review medical journals including The Canadian Journal of Infectious Diseases & Medical Microbiology.  
**Ann LeBlanc**  
**VICE-PRESIDENT**  
2902 South Sheridan Way  
Oakville, Ontario L6L 5T7  
Phone: (905)829-4770  
Fax: (905)829-4799  
Email: a.leblanc@pulsus.com  
Website: www.pulsus.com

**Qiagen Inc.**  
**BOOTH # 54**  
Qiagen’s molecular diagnostic Sample and Assay Technologies cover all application areas in healthcare, including: screening of asymptomatic patients (prevention) and testing of patients who are at risk of carrying a disease (profiling).  
**Jeff Christiansen**  
** SENIOR SALES DIRECTOR**  
27220 Turnberry Lane  
Valencia, California 91355 USA  
Phone: (661)702-3000  
Email: jeff.christiansen@qiagen.com  
Website: www.qiagen.com

**Quidel Corporation**  
**BOOTH # 30**  
Quidel® Corporation is a leading manufacturer of diagnostic healthcare solutions for women’s health, as well as respiratory, gastrointestinal and other infectious diseases.  
**Alanna Prasad, PhD**  
**ASSOCIATE SALES DIRECTOR, CANADA**  
10165 McKellar Court  
San Diego, California 92121 USA  
Phone: (647)527-6074  
Fax: (858)431-3558  
Email: aprasad@quidel.com  
Website: www.quidel.com

**Roche Diagnostics**  
**BOOTH # 19**  
Roche Diagnostics, a division of Hoffmann-La Roche Ltd., is the world leader in in vitro diagnostics and offers a uniquely broad product portfolio and innovative solutions to researchers, physicians, hospitals and laboratories in the fields of diabetes care and anticoagulation therapy, molecular biology, diagnostic in-situ, clinical chemistry, immunology and applied science.  
Email: laval.marketing_diagnostics@roche.com  
Website: www.roche.ca

**Somagen Diagnostics Inc.**  
**BOOTH # 37**  
As Canada’s leading laboratory diagnostics distribution company, we represent an expanding portfolio of innovative products and technologies for microbiology and infectious disease testing.  
**Jaylene Laviole**  
**DIRECTOR OF BUSINESS DEVELOPMENT**  
9220 - 25 Avenue  
Edmonton, Alberta T6N 1E1  
Phone: 1(800)661-9993  
Fax: (780)438-6595  
Email: info@somagen.com  
Website: www.somagen.com

**Sunovion Pharmaceuticals Canada Inc.**  
**BOOTH # 52**  
Sunovion Pharmaceuticals Canada Inc. is focused on the commercialization of prescription products in Canada. Our strategy is to license pharmaceuticals products that meet the needs of patients and the Canadian health care system. We are focused in the areas of cardiology, central nervous system and infectious disease.  
**Paul Peters**  
**BUSINESS UNIT MANAGER, CUBICON**  
100 - 6790 Century Avenue  
Mississauga, Ontario L5N 2V8  
Phone: (905)814-9145  
Fax: (905)363-0162  
Email: paul.peters@sunovion.com  
Website: www.sunovion.ca

**Starplex Scientific Inc.**  
**BOOTH # 59**  
Starplex Scientific Inc. specializes in premium quality collection and transportation devices including Leakbuster TM containers and Starswab II TM transport swabs.  
**Fred Turco**  
Phone: 1(800)665-0954  
Email: info@starplexscientific.com  
Website: www.starplexscientific.com
Thermo Scientific - Oxoid, Remel and TREK Products
BOOTH # 16
The industry-leading Thermo Scientific product portfolio features Oxoid prepared media, VersaTREK™ automated blood culture and Sensititre™ AST/MIC solutions. Our products are renowned for quality, accuracy and reliability.

100 - 1926 Merivale Road
Nepean, Ontario K2G 1E8
Phone: 1(800)267-6391
Email: o xo.id.ca.webinfo@thermofisher.com
Website: www.thermoscientific.com/microbiology

Trinity Biotech - Nova Century Scientific
BOOTH # 64
Trinity Biotech / NCS offers an extensive line of diagnostic kits for the following: Enterics, ToRCH, Measles, Mumps, VZV, EBV, STD, Lyme, Sepsis and Respiratory Identification.

Kim Kouri
ACCOUNT MANAGER
5022 South Service Road
Burlington, Ontario L7L 5Y7
Phone: (514)619-2764
Toll-free: (800)615-5072
Fax: 1(800)639-9006
Email: kkouri@novacentury.com
Website: www.trinitybiotech.com

Valeant
BOOTH # 57
Valeant Canada has a diverse product portfolio in several therapeutic areas, including Pain Management, Cardiovascular Disease, Neurology, Dermatology and OTC, and we continue to expand these areas with new offerings.

Ed Komsky
SENIOR HCP SPECIALIST
520 Applewood Crescent
Vaughan, Ontario L4K 4B4
Phone: (905)695-7727
Email: ed.komsky@valeant.com
Website: www.valeantcanada.com

CFID Bug Run
Join your colleagues, friends, competitors or just challenge yourself in a 5K Bug Run/Walk sponsored by the Canadian Foundation for Infectious Diseases on Friday, April 17, in Charlottetown. Shake out the cobwebs and run off a few calories in anticipation of dinner, after a fascinating day of meetings, by putting on your running gear and joining us for a run in support of research and education in infectious diseases….. and still be in time for drinks and dinner!

Registration starts at 5:30 PM and the race will begin at 6:15 PM. The race will start from a location right near the Delta Prince Edward Hotel: exact location for registration and race route to follow. Or pre-register online (see below).

Keep posted about details on the Running Room website: https://www.events.runningroom.com/site/?raceld=11849

Looking forward to seeing you there!